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Cognitive decline and dementia are common non-motor impairments associated with Parkinson’s
disease (PD). White matter hyperintensities (WMHs) are vascular MRI findings that are common
in older individuals and have been shown to be associated with cognitive impairment. This study
aims to assess the predictive power of WMH volume and spatial location on cognitive impairments
in PD using an automated WMH identification algorithm and MRI.
A training data set of 40 subjects with high WMH volume were used to assess the performance
of 4 automated WMH detection algorithms against gold-standard manually identified WMH maps.
The optimal algorithm was then applied to a longitudinal PD cohort (PD=207, HC=51) and cog-
nitive impairment and dementia prediction were investigated using Bayesian regression modelling
and model comparisons. Specifically, I investigated the relationship between global and regional
WMH volumes, global cognitive ability, and individual cognitive domain scores.
Brain Intensity AbNormality Classification Algorithm (BIANCA) was the identification algo-
rithm that resulted in the most accurate and precise WMH maps in our training set. BIANCA was
used with optimised parameters to extract WMH maps for the whole cohort. I found no evidence
of increased global WMH burden in PD relative to healthy controls, nor any difference across cog-
nitive ability within PD. Furthermore, I found no significant spatial relationship between WMH
volume and global cognition, however anterior periventricular WMHs (PVWMHs) associated with
attention and executive function cognitive domains.
These results suggest that WMHs are not a clinically-relevant biomarker of cognitive impairment
in PD. While there is a weak emerging correlation between increased anterior PVWMH volume
i
and specific cognitive domain dysfunction, resounding support of regional WMHs prediction of
cognitive domain dysfuncytion is lacking.
ii
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Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting the pop-
ulation, with an estimated 1 in 500 individuals in New Zealand with PD in 2013 [33]. PD is a
debilitating disease, and its prevalence increases exponentially with age [26], which is of particular
importance in a community with an aging population. Historically, PD has been viewed as a motor
disorder, however, development in the understanding of PD in recent decades indicates a myriad
of non-motor impairments are also associated with the disease [34].
1.1.2 Pathology
PD is classically characterised by hallmark motor symptoms; namely resting tremor, bradykinesia,
gait impairment, and rigidity [26]. The associated non-motor symptoms that have emerged in re-
cent decades include, but are not limited to, olfactory impairment, sleep and cognitive impairments,
hallucinations, depression, apathy, anxiety, and autonomic dysfunction [26, 35]. PD is understood
to be a multi-system disorder, clinically heterogeneous in nature and associated with a number of
protein aggregates and neuromodulatory systems involved [26].
The basal ganglia (BG) are subcortical structures deep within the forebrain that are made up of a
1
number of nuclei that each play a different role across a number of motor and cognitive processes
[17]. The neurological pathways of the BG contribute to the execution or inhibition of movement
via projections to the frontal cortex through the thalamic nuclei [17]. The substantia nigra (SN),
so-called due to its blackened appearance compared to surrounding tissues, is a nucleus in the BG
and is separated into two regions; the dopamine-rich pars compacta (SNpc), and the pars reticular
(SNpr). See Figure 1.1 for the basic structure of BG and constituents. Dopaminergic neurons are
housed within the SNpc and project to the caudate-putamen, with dopamine playing a vital role
in voluntary motor movement, mood, and emotion control [9, 17]. A reduction in the quantity
of dopamine produced is thus closely related to the disruption of the systems underlying these
functions. In PD, mass cell degeneration and death of dopamine neurons in the SNpc contribute
to the depletion of dopamine that occurs with the development of the disease and it is estimated
that an individual with PD will lose 50-80% dopaminergic cells in the duration of the disease
[5]. The mechanism of dopaminergic neuron death in PD remains unknown, resulting in treatment
strategies focused on alleviating symptoms, rather than altering the underlying cause of the disease.
Figure 1.1: Basic basal ganglia and nuclei structure. Striatum (blue), pallidum (pink), subthalamic
nuclei (green), and substantia nigra (yellow) [17]
The current gold standard for diagnosis of PD is in postmortem investigation of the presence of
misfolded α-synuclein protein and degradation of the SNpc [26]. In practice, the diagnosis is made
clinically at times supported by adjunctive methods such as DAT-SPECT imaging, with correct
clinical diagnosis of PD pathology in 84% of cases [52, 60]. Although the development in imaging
techniques in past decades have provided the potential for in vivo disease identification, there are
currently no unequivocally recognised biomarkers of PD that can be identified in neuroimaging
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techniques such as MRI [29].
To date, treatment avenues are focused on symptomatic regulation as opposed to disease cure [26].
Treatment focus is placed on improving a patient’s quality of life and controlling the inhibiting
symptoms when possible. The areas of disease manifestation that are focused on for treatment
include the motor symptoms, psychosis, mood, and autonomic dysfunction [10]. Pharmaceutical
treatment options that target the issue of dopamine deficiency are largely used to treat the motor
symptoms of PD, with common pharmaceutical options including Levodopa and dopamine agonists
[9, 10, 26]. It is common that numerous symptoms require treatment as heterogeneity of symptoms
and progression make a single treatment an unlikely solution for this disease.
1.1.3 Cognition in Parkinson’s disease
Cognitive impairment is a non-motor problem that affects a large number of PD patients and it is
estimated that 80% of PD patients will develop dementia over the course of their disease [5, 21].
One framework for considering cognitive impairment in PD groups patients into those with nor-
mal cognition (PD-N), those with mild cognitive impairment (PD-MCI), and those with dementia
(PDD). Assessment an individual’s overall cognitive status often requires rigorous cognitive testing
to assesses all cognitive domains, including executive function, attention, visuospatial, learning and
memory, and language domains [1]. There are international guidelines from the Movement Disorder
Society (MDS) task group for the diagnosis of the cognitive status of PD patients. PD-MCI refers
to an individual with PD who experiences minimal impairment in daily life but whose cognitive
test scores in at least one cognitive domain fall below 1.5 SD of the mean age-adjusted normative
data or control data [13]. PD-MCI is considered an intermediate cognitive stage between normal
cognition and dementia. PDD refers to a PD patient who experiences significant interruption to
everyday activities due to cognitive impairments, not caused by motor impairments. Clinically,
PDD is defined by cognitive scores 2 SD below the mean of age-adjusted normative data in at
least two cognitive domains. Many studies have characterised the mechanisms of cognitive decline
in PD including both postmortem and in vivo studies [1], however, no singular definitive cause of
cognitive decline in PD has been determined yet.
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One theory of the characterisation of cognitive decline in PD is the dual syndrome hypothesis. This
characterisation details degradation of specific cortical regions resulting in specific cognitive domain
impairments. The hypothesis differentiates between two independent PD syndromes; the first that
fronto-striatal dysfunction is indicative of planning, working memory, and executive function im-
pairments, and the second, that non-frontal dysfunction is indicative of visuospatial impairment
[27, 48]. In addition to visuospatial impairments, it is suggested that non-frontal syndrome is
thought to lead from PD-MCI to PDD more rapidly than the frontal syndrome [22]. The validity
of this hypothesis is of keen interest in the characterisation of cognitive impairment in PD and will
be investigated in this thesis.
Neuropsychological testing is insufficient to identify those individuals most at-risk of progressing
quickly from PD-MCI to PDD, thus additional information is required if we are to identify the most
at risk patients. Identification of this group with heightened PDD development risk is advantageous
as novel treatments or trials can be targeted towards the group. Neuroimaging is a powerful and
promising technique which may provide us with this additional information required to determine
the state of an individual’s brain health at present and in the future. Neuroimaging also has the
potential to be a tool for identifying biomarkers of cognitive impairment in PD. Such biomarkers of
cognitive decline and dementia are urgently needed to enrich treatment samples with those more
likely to develop dementia in the near future, as well as potentially to assess treatment effectiveness.
White matter hyperintensities are one such biomarker holding PD cognition prediction potential.
1.2 White matter hyperintensities
1.2.1 Overview
Cerebral small vessel disease (CSVD) is an umbrella term to describe brain pathologies that are
through to arise from changes within cerebral arterioles, capillaries, and small blood vessels [49].
They are visible on MR images with manifestations including, but not limited to, subcortical infarcts
(lacunae), cerebral microbleeds, and white matter hyperintensities (WMHs) [49]. Developments in
medical imaging techniques have improved our ability to visualise CSVD and the associated expres-
sions of the pathology, allowing for an investigation into their cause, development, and consequences.
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WMHs appear as bright areas of white matter (WM) visible on MR images, specifically, proton den-
sity weighted, T2-weighted, and T2-weighted fluid-attenuated inversion recovery (FLAIR) images.
The properties of these MR techniques make them sensitive to vascular damage [8, 37]. WMHs
have been observed in individuals of varying levels of health, but they are consistently associated
with increasing age, and traditional cardiovascular risk factors such as hypertension [24, 38, 53],
and the presence of WMHs has been related to impairments in balance, mobility, and cognition
in otherwise healthy individuals [5, 49]. In addition to these reported impairments, it has been
suggested that the presence of WMHs modulate the severity of a number of diseases like stroke,
Multiple Sclerosis (MS), Alzheimer’s disease (AD), and PD [24].
WMHs can be present through the entire mass of white matter, however, they tend to follow a
characteristic distribution. There are regions of WM that are generally not affected (e.g. juxtacor-
tical) but regions around the ventricles are often observed [36]. Total WMH burden can thus be
separated into deep WMHs (DWMHs) and periventricular WMHs (PVWMHs) dependant on their
distance from the ventricles. While the definition of WMHs spatial location has been developed,
questions remain on the relative importance of these WMH classifications in terms of pathologies
and impairments [18].
1.2.2 White matter hyperintensity identification
For WMH volume to be used in any research or clinical capacity, accurate identification is of utmost
importance. Historically, WMH burden has been assessed by an experienced grader using various
scales used to classify WMHs; Fazekas scale [15] and Scheltens scale [45] for example. These scales
are reliable WMH identification methods when followed by an experienced grader, however, they
do not provide any information on the specific location of WMH burden in an individual [19].
Technological developments in previous years have made manual segmentation of WMHs an option
for burden assessment in which a grader can manually identify WMH voxels on a medical image,
slice by slice. This technique has the advantage of providing spatial information and accurate
qualification about the WMHs that the previously mentioned rating scales cannot provide. While
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such manual rating techniques have high success in the identification of WMHs, they are time-
consuming and can be variable based on inter- and intra- grader differences [19, 46]. Furthermore,
large cohorts and medical images of high spatial resolution render manual identification impracti-
cal because of the time-consuming nature of the work. Therefore, there is a need for a detection
technique that is immune to the issues faced by manual grading while also being reliable and robust.
There are a number of automated and semi-automated algorithms available for WMH identification,
yet there is no gold standard identification method, much less one specific for WMHs in PD. The
available literature for these automated identification techniques reports success in their respective
cohorts, however, variability in data such as MR acquisition, image quality, and cohort can all
contribute to the variability of success when any given technique is used on another cohort [19, 24,
47, 51]. The lack of a gold-standard automatic identification technique also means that different
papers use different identification techniques which limits comparability, which further contributes
to the confusion surrounding the significance of WMHs on specific pathologies.
1.2.3 White matter hyperintensities and cognition
In MS, WMHs have been shown to be related to “irreversible neurological disability” by damage
to WM tracts that connect the cortex to nuclei (such as the constituents of the BG) [4], and WM
lesions are a known biomarker of the disease [47]. There are many automated and semi-automated
WMH identification algorithms that have been created specifically for WM lesion identification in
MS. WMHs have also been shown to exasperate cognitive decline in AD, with this relationship
being widely accepted and agreed upon [8, 16]. In addition to contributing to worsening cognition
in cohorts with neurological disease, there is also an association between healthy individuals’ wors-
ening cognition and increased WMH burden [28].
The association between WMHs and cognitive impairment and decline in PD is based on the effect
WMHs have on cortical connection and WMH tracts that have been found in other diseases, such as
MS as mentioned above. Studies have been carried out claiming that WMHs may cause or worsen
cognition in PD with PVWMHs potentially interrupting ascending thalamocortical and descending
corticospinal fibres causing cognitive impairments [5]. Spatial location of WMHs, therefore, may
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have different clinical consequences corresponding to the association fibres in the region of WM
damage [50].
The dual syndrome hypothesis, as introduced above, suggests that spatial location of WMHs could
be an important influencer of different cognitive dysfunction patterns. In terms of WMHs, this hy-
pothesis suggests that PVWMH burden could be indicative of specific cognitive impairments in PD,
allowing for categorisation of the cognitive impairment. Specifically, it is suggested that anterior
PVWMHs cause executive function and attention domain dysfunction, while posterior PVWMHs
cause memory and visuospatial domain dysfunction.
A recent study by Reginold and colleagues investigated the diffusion properties of WM tracts in the
presence of WMHs and reported that WM fibre tracts that crossed WMHs exhibited abnormal diffu-
sion characteristics, which can be related back to the dual syndrome hypothesis with WMH location
associated with dysfunctional WM fibres [41]. The study also found that diffusion characteristics
of WM tracts worsened when they were located close to a WMH. These findings indicate there is
potential benefit in knowing the location of WMHs in an individual to specify their particular PD
related cognitive impairments, future cognitive decline, and assist in identifying patients that can
be targeted for novel treatments as they are developed. This being said, research into the relation-
ship between WMHs and spatial location and the combined effect on cognition in PD is still needed.
The literature reviewed for this study indicated a divide in findings of correlation between WMHs
and cognitive impairment in PD. While some studies reported significant correlation between
WMHs and cognitive impairments, others fail to emulate the same findings [12, 16, 31, 53]. For
this reason, an investigation into WMHs in PD in our large, longitudinal PD cohort is of interest
due to the potential predictive power of WMHs of cognition in PD.
1.3 Study rationale and breakdown
The aim of this thesis was to investigate the importance of WMHs as a biomarker of cognitive im-
pairment in PD. MRI and automated WMH identification algorithms were used to detect WMHs
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in a large PD cohort. First, in a training cohort, I tested four WMH identification algorithms and
compared them to ‘gold standard’ manually segmented WMHs map in order to select the optimal
automated method. I then applied the optimal method to the full cohort, producing WMHs maps
in all individuals. Next, I investigated the relationship between WMHs, PD, and cognitive impair-
ment, in a cross-sectional and longitudinal manner.
The motivation for determining the relationship between WMHs and cognitive impairment is the
potential of finding a biomarker that indicates an individual’s risk of developing cognitive impair-
ment in PD. With the research into the correlation of cognition and WMH in PD unequivocal to
date, this study aims to detail the correlation of WMH volume to cognition in our large PD cohort.
In addition, an objective marker of disease severity (i.e. WMHs) could also be used to assess the
effectiveness of any novel treatments.
This thesis is set out in 2 parts:
Part 1: Training, assessment, and selection of a method to automatically identify WMHs within
our cohort.
Part 2: Application of the automated algorithm identified in Part 1 to all participants to determine:
• Do WMHs differ between PD and controls cross-sectionally?
• Do WMHs differ across cognitive groups (i.e. control, PD-N, PD-MCI, PDD) at both the
global and regional level?
• Does global and/or regional WMH volume can predict future global cognition?




An overview of magnetic resonance imaging (MRI) is presented here as the imaging modality is
utilised extensively in this study. MRI an imagining technique that utilises magnetic properties of
protons to create highly detailed diagnostic images. MRI exploits the presence of hydrogen in the
body, with differences in hydrogen content in various tissues contributing to image contrast. A hy-
drogen nucleus has an associated magnetic moment produced by the nuclear spin of the constituent
proton about its axis. When subject to external magnetic field changes, the magnetic moments
exhibit certain properties which can be perturbed and recorded to yield an MRI signal.
A sample of magnetic moments will self arrange in a disorganised, random orientation in which
all magnetic moments cancel each other out, resulting in no net magnetisation. However, when
exposed to an external magnetic field, B0, the protons tend to align with the external magnetic
field, yielding a net magnetisation, M along the direction of B0. In addition, the external magnetic
field exerts a torque on the protons that causes an alteration in spin precession proportional to B0
and the gyromagnetic ratio of the particular element, γ = 42.58MHzT−1 for hydrogen [7]. The
angular frequency of this spin precession is calculated by the Lamour equation and is a cornerstone
in MRI (Equation 2.1)
ω = γB0 (2.1)
.
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The Lamour frequency ω is also the resonant frequency of the sample. Exposure to an external
radiofrequency (RF) pulse at the resonant (Lamour) frequency causes the net longitudinal mag-
netisation to rotate away from the longitudinal (along the z-axis) into the transverse plane (the
xy-plane). The flip angle is the angle between the original net magnetisation and the net magneti-
sation vector when the resonant RF pulse is turned off. The net magnetisation in the xy-plane
continues to precess and induces a current in a receiver coil. This orientation is not sustainable,
so the protons will eventually revert to the original equilibrium and the strong signal from the
rotating net longitudinal mangetisation precessing in the xy-plane decays. Precession of the net
magnetisation in the transverse plane (xy-plane) produces the raw MR signal. The properties of
the sample will determine the rate of the return to equilibrium, which is recorded and used in the
MR image construction [7].
2.0.1 Relaxation
Relaxation is the process by which an excited sample loses energy and returns to equilibrium; there
are two chief methods of relaxation in MRI.
• T2 relaxation or spin-spin relaxation in which energy obtained by a sample from the
resonant RF pulse is dissipated through inhomogeneities in the sample.
• T1 relaxation or spin-lattice in which energy obtained by a sample from the resonant RF
pulse is released into the lattice of surrounding molecules.
Factors dictating both T1 and T2 relaxation times include molecule size, motion, and interactions.
Figure 2.1 indicates how the two relaxation times change dependant on these factors, and a consis-
tently longer T1 relaxation time is observed. Another fundamental principle behind MRI is that
different tissue types exhibit different characteristic T1 and T2 relaxation times. MRI can, there-
fore, be tuned to accentuate these differences to create images exhibiting different contrasts and
encompassing different biological information, discussed below in Section 2.0.2.2.
2.0.2 MRI acquisition parameters and pulse sequences
There are a number of core parameters that can be manipulated to produce different types of MRIs.
These inclue:
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Figure 2.1: T1 and T2 relaxation comparison and the factors affecting differing relaxation times
[7].
• Time of Repetition (TR): The time between excitation RF pulses, B1, applied to B0.
• Time of Echo (TE): The time between the excitation RF pulse and the returning signal echo’s
peak.
• Time of Inversion (TI): The time between a 180-degree inversion RF pulse and the 90-degree
excitation RF pulse.
Spin echo (SE), gradient echo (GE), and inversion recovery (IR) are the main pulse sequences that
use different combinations of TR, TE, and TI to produce images with different contrasts. For
example, the TE and TR can be adjusted to create T1-weighted images and T2-weighted images.
2.0.2.1 Gradient echo
GE is a sequence that uses a magnetic field gradient to create an signal echo. After a 90-degree FID
inducing pulse, the gradated magnetic field rapidly dephases the FID until an equal and opposite
gradated magnetic field is applied to rephase the FID. The application of the two gradients induces
the GE with relaxation of FID dictated by tissue and static field inhomogeneities [32], which is
detected, recorded, and used in image reconstruction. T1-weighted spoiled gradient echo sequence
is used in this study for the structural images defining GM, WM, and brain structures in which
T1-weighted sequenced can be delivered and images acquired rapidly [32], detailed in Section 4.3.
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2.0.2.2 Spin echo
SE is a sequence in which a sample is initially excited and an FID is induced with a 90-degree pulse,
followed by a 180-degree pulse that produces an echo for measurement. The initial excitation cre-
ates the transverse magnetisation that immediately begins to decay, and the following refocusing
pulse inverts the system and induces phase coherence and peak echo amplitude at TE. The system
then decays through usual mechanisms towards the restoration of equilibrium. Multiple 180-degree
pulses can be applied subsequently to obtain a series of echoes that diminish according to the T2
relaxation time of the sample.
T1-weighting: One particular SE sequence used extensively in medical MRI is the T1-weighted
sequence which exploits T1 characteristic differences in the sample to achieve significant contrast
in the resultant images. This sequences uses a short TR in which different tissue types have vastly
different signals, and pair it with a short TE to capture this difference. This combination of TR
and TE is shown in Figure 2.2a, where the tissues with different molecular structures respond to
the excitation RF pulse along different growth curves. T1-weighted images create high-resolution
structural images with high levels of contrast between GM, WM, and CSF.
T2-weighting: T2-weighting exploits T2 characteristic differences in tissues by combining long
TR and TE times. The long TR time allows the signals to recover sufficiently, and a long TE allows
the signals to decay according to spin-spin relaxation. The resultant growth and relaxation curves
are shown in Figure 2.2b. T2-weighted images have high soft tissue contrast, although the long TE
increases image noise.
It is shown graphically in Figures 2.2a and 2.2b how different choices of TR and TE can have
a significant influence on the image contrast of a particular scan. Therefore, careful selection of
these times and their combinations are needed to acquire images that are clinically useful and
informative.
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(a) T1-weighted longitudinal recovery (L) and transverse decay
(R) for 4 brain tissues.
(b) T2-weighted longitudinal recovery (L) and transverse decay
(R) for 4 brain tissues.
Figure 2.2: Signal recovery as dictated by a combination of TI and TE [7]
2.0.2.3 Inversion recovery
Inversion recovery (IR) is a sequence used to suppress the response of specific tissues according
to T1 characteristics. The sequence involves an inversion pulse of 180-degrees to invert the net
magnetisation after which signal recovery begins as the magnetisation returns to equilibrium. A
90-degree pulse is applied after a given inversion time (TI) to transfer the recovered signal back to
the transverse plane generating the FID. A secondary 180-degree pulse is applied at TE/2 to re-
trieve the signal echo for reading at TE. Dependant on the TI selected, the signal from tissues with
particular molecular structures can be nulled, changing the contrast to highlight various regions of
interest.
Fluid-attenuation inversion recovery (FLAIR): FLAIR imaging nulls signal of fluids with
long T1 relaxation times. The TI for a FLAIR sequence is selected so when the 90-degree pulse
is applied, there is no Mz signal to send to the transverse plane, thus effectively nulling the signal
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[44]. The FLAIR sequence is shown in Figure 2.3. While grey and white matter are difficult to
differentiate in FLAIR images [32], the images are very sensitive to small vessel disease, which
manifest as white matter hyperintensities. Therefore, this thesis utilised T2 FLAIR images to
identify white matter hyperintensities.
Figure 2.3: The sequence of RF pulses that form a FLAIR sequence and the relative recovery of






WMHs are potentially valuable biomarkers for a number of diseases, including PD. To date, the ac-
cepted gold-standard method of identifying WMHs in MRI scans is manual detection by an expert
grader [24]. This time-intensive process is not completely free from possible errors, however, and
is practically unusable in large cohorts with many scans that require WMH detection. Therefore,
an automated method of WMH detection is desirable, especially one that is robust and accurate.
There are currently a number of automated WMH detection methods available for use, however,
these methods are accompanied by particular advantages and disadvantages dependant on a myriad
of factors. For instance, methods specifically designed to detect MS lesions may not be optimised
for WMH detection in other diseases due to the differences in sharpness of the edge of the hyperin-
tensities [19]. While the selection of an identification algorithm based only on published literature
is an option for identifying WMHs in PD [19, 31, 56], in this thesis I directly applied and tested




Here, I have set out to optimise and test four WMH algorithms. To do so, I manually traced WMHs
on a group of PD participants under the supervision of a neuroradiologist. This set of manually
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defined WMHs became the ‘gold-standard’ used to test the outputs of the four algorithms. A subset
of the full study cohort was used as the training cohort since restricting the number of subjects
in the training stage of this study reduced the time required to train and test the algorithms
while maintaining adequate accuracy. Initially, the training cohort comprised 20 subjects with
subjectively high WMH burden and were selected by global WMH volume as calculated by an
initial run of a WMH identification algorithm. High burden subjects were used in the training
cohort because it is suggested that high WMH burden is easier to visually identify, and an increased
number of WMH voxels provides the algorithms with more learning opportunities in training to
apply to new subjects, resulting in more accurate WMH detection when applied to non-training
subjects [19, 23].
3.1.2 Creation of manual masks
To assess the performance of the algorithms under investigation, WMH masks were required as
a ‘gold-standard’ benchmark of performance. I manually identified WMHs on FLAIR images of
the training subjects using FSLview (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FslView). Dr. Ross
Keenan, a neuroradiologist, supervised and ensured accurate ‘gold-standard’ masks were created.
Care was taken when creating the manual masks to ensure false positives were not included, and
WMH clusters smaller than 5 mm in diameter were excluded per the European Task Force on Age-
related White Matter changes recommendations [57]. These very small lesions are said to be caused
by image noise and partial voluming effects and thus should be excluded from the WMH masks
[57]. I took particular care to avoid scoring the septum pellucidum as the signal can mimic true
WMHs. At the first review, the manual masks I created were advised to be too liberal and included
false positives, particularly adjacent to the ventricles. These masks were revised and approved by
Dr. Keenan. For the remainder of this thesis, I will refer to these manually traced WMH masks as
’manual masks’.
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3.1.3 Performance measures for algorithm selection
3.1.3.1 Performance measure terminology
To understand the performance measures used to assess algorithm ability to identify WMHs it is
essential to understand the terminology and definitions of the variables the metrics employ. The
variables used in this study are as follows:
• True positive (TP): a voxel assigned to the WMH mask by an algorithm that is also
included in the manual mask.
• True negative (TN): a voxel excluded from the WMH mask by an algorithm that is also
excluded from the manual mask.
• False positive (FP): a voxel assigned to the WMH mask by an algorithm but is excluded
from the manual mask.
• False negative (FN): a voxel excluded from the WMH mask by an algorithm but is included
in the manual mask.
• Detection error (DE): the sum of voxels in false positive and negative clusters detected by
the algorithm.
• Mean total area (MTA): the average total WMH volume by the manual mask and algo-
rithm output.
3.1.3.2 Performance measurement metric
The Dice Similarity Index (SI) was used to quantify the similarity between the manual masks and
the algorithm produced masks. SI compares the two masks on a voxel-wise level (equation 3.1).
That is, SI is a ratio of TP, to TP, FP, and FN voxels between the manual and algorithm-generated
masks. Secondary metrics included false negative rate (FNR), false positive rate (FPR), and de-
tection error rate (DER) (equations 3.2, 3.3, 3.4, respectively). These three similarity metrics were
chosen since a “...good balance through all DSC[Dice Similarity Coefficient], sensitivity, specificity
and precision scores” [39] is needed for a learning algorithm to be considered successful. The cal-
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culation of performance measures was carried out in FLAIR space for all algorithms to ensure
consistency and legitimacy in comparison.
SI =
2× TP
2× TP + FP + FN
(3.1)
FNR = 1− TN
TN + FP
= 1− specificity (3.2)
FPR = 1− TP
TP + FN





The four algorithms investigated in this study produce WMH probability maps; that is, each voxel
value represented the likelihood of a region being a WMH from 0-1. In order to compare WMH
probability maps to the manual masks, one needs to define a threshold to produce a binary mask.
The threshold value is user defined and can vary dependant on the algorithm under investigation.
For the remainder of this thesis, I will refer to binary, thresholded WMH probability maps as ‘al-
gorithm output masks’.
The following sections present and assess the performance of the 4 individual identification algo-
rithms chosen for investigation. For each algorithm, I present an overview of how it works, the
required training data and preprocessing steps required, the results of the algorithm, and any ad-
justments made in an attempt to improve the results. The algorithms I assessed were BIANCA,
LPA, LGA, and UBO Detector [19, 23, 46, 47].
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3.2 Brain Intensity AbNormality Classification Algorithm: BIANCA
3.2.1 BIANCA algorithm overview
BIANCA is an algorithm developed in 2016 [19] and made available through FSL
(https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/BIANCA). It is a supervised, automatic method for WMH
detection based on k-nearest neighbour (k-NN) classification. According to a k-NN algorithm,
the classification of a voxel of interest x is dictated by the k neighbours and is probabilistically
dependant on the relative classifications of the neighbours. k = 40 is utilised by BIANCA based
on initial performance assessment and literature [19, 51]. Training data in the form of manually
identified WMHs is required for k-NN classification as the algorithm uses the positive instances in
the manual masks as knowledge for the classification outputs of the algorithm. WMH identification
performed by BIANCA depends heavily on the spatial location of the data point of interest as well
as intensity. Since WMHs are only expected to be located in the WM, a higher probability can
be given to x that falls with WM. BIANCA can be run such that a linear scaling factor is used
to restrict the algorithm to using study-specific training data, improving the accuracy of WMH
identification. After BIANCA is run, a post-processing step in which the probabilistic output maps
of BIANCA are made binary by excluding any classified data under a user-controlled threshold.
The algorithm output masks can then be compared to the manual masks and similarity measures
calculated for assessment and comparison to other tested algorithms.
BIANCA was trained and optimised on the 20 selected training subjects. Unbiased training and
assessment of performance for any given training specifications and parameters are of great im-
portance. Therefore, BIANCA, uses a leave-one-out (LOO) cross-validation component in which
one training subject is removed from the training data set, cohort size = n, and BIANCA is then
trained using the remaining n− 1 subjects before the resultant algorithm is applied to the one test
subject who was excluded from training. The WMH probability map for each subject in the testing
data set is, therefore, independent of training data.
More detailed workings of BIANCA can be found in the 2016 paper by Griffanti et al. [19].
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3.2.2 BIANCA data preparation
BIANCA requires two input images for segmentation I used T1 and T2 FLAIR images in this
study. One of the images must be brain extracted and both must be registered to a common space.
Four combinations of brain extracted T1 or T2 FLAIR images in either T1 or T2 FLAIR space
were trailed initially to determine which combination produced better results (i.e. higher similarity
between manual masks and algorithm-derived masks). These four combinations are as follows;
FLAIR space with brain extracted FLAIR image, FLAIR space with brain extracted T1 image,
T1 space with brain extracted FLAIR image, and T1 space with brain extracted T1 image. FSL
FMRIB’s Linear Image Registration Tool (FLIRT) was used for registration of images to different
base spaces. SPM12’s registration check tool was used to ensure the registration of both T1 image
to FLAIR space and FLAIR image to T1 space was accurate.
FSL Brain Extraction Toolbox (BET) was used originally for brain extraction of T1 and FLAIR
images, however, the brain extraction of FLAIR images were not truly representative of the brain,
namely eyes and skull were included in many brain-extracted images. This poor performance could
be due to the lower resolution of the FLAIR images compared to T1 images 32 z slices compared
to 170 z slices, respectively. To combat this, binary brain masks of T1 images were produced by
FSL BET and multiplied with the FLAIR images in FLAIR space, resulting in far more accurate
brain-extracted images.
3.2.3 Initial BIANCA results
BIANCA was run on the 20 training subjects using default optimised specifications from the 2016
paper that first presented BIANCA by Griffanti et al. [19]. For this initial training, I used a
post-processing threshold of 0.95. Table 3.1 shows the results from this initial training.
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Table 3.1: BIANCA results comparing input images in different spaces at post-processing threshold
= 0.95. FLAIR space, brain extracted FLAIR images resulted in best performance measures.
Optimal performance is indicated in bold.
Trial SI Voxel FPR Voxel FNR DER
Trial 1: FLAIR space, brain extracted FLAIR 0.69 ± 0.02 0.06 ± 0.01 0.44 ± 0.02 0.07 ± 0.01
Trial 2: FLAIR space, brain extracted T1 0.45 ± 0.17 0.13 ± 0.13 0.65 ± 0.18 0.11 ± 0.11
Trial 3: T1 space, brain extracted FLAIR 0.57 ± 0.04 0.08 ± 0.02 0.56 ± 0.04 0.13 ± 0.04
Trial 4: T1 space, brain extracted T1 0.37 ± 0.04 0.11 ± 0.03 0.74 ± 0.04 0.20 ± 0.06
Results presented as mean values ± standard deviation. Legend: SI = Similarity Index; FPR = False positive rate;
FNR = False negative rate; DER = Detection error rate.
All 4 initial trials, which used a conservative threshold of 0.95, had a relatively high FNR and a
low FPR, (Table 3.1). Ideally, both false negative and positive rates would be as low as possible
for the most accurate results; a high FNR indicates the algorithm has failed to detect the lesions
identified in the manual masks, and a high FPR indicates the algorithm has incorrectly identified
regions as WMHs when they haven’t been manually identified as WMHs.
Trial 1 (FLAIR space, brain extracted FLAIR) had the highest SI for the post-processing thresh-
old of 0.95, perhaps due to the minimal registration of images to new space needed in the data
preparation, and thus was selected as the image registration scheme to be subsequently used. After
establishing the input data scheme, I tested the effect of different post-processing thresholds. 20
equally spaced thresholds between 0-1 were tested, with the magnitude of SI, FPR, FNR, and DER
compared across all thresholds (Table 3.1). The threshold value 0.8 was selected as it produced
the highest mean SI = 0.76± 0.02, although consideration of voxel FPR and FNR, and DER were
considered in the selection of the optimal threshold value.
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Table 3.2: BIANCA results at various post-processing thresholds, 20 training subjects. Threshold
= 0.8 resulted in the best performance measures. Optimal performance is indicated in bold.
Threshold SI Voxel FPR Voxel FNR DER
0.05 0.28 ± 0.03 0.83 ± 0.02 0.02 ± 0.00 0.03 ± 0.00
0.1 0.36 ± 0.03 0.77 ± 0.02 0.03 ± 0.00 0.04 ± 0.00
0.15 0.43 ± 0.03 0.71 ± 0.03 0.04 ± 0.01 0.05 ± 0.00
0.2 0.48 ± 0.03 0.67 ± 0.03 0.06 ± 0.01 0.06 ± 0.01
0.25 0.52 ± 0.03 0.62 ± 0.03 0.07 ± 0.01 0.06 ± 0.01
0.3 0.56 ± 0.03 0.58 ± 0.04 0.09 ± 0.01 0.07 ± 0.01
0.35 0.61 ± 0.03 0.51 ± 0.04 0.11 ± 0.01 0.07 ± 0.01
0.4 0.63 ± 0.03 0.49 ± 0.04 0.12 ± 0.01 0.07 ± 0.01
0.45 0.67 ± 0.03 0.43 ± 0.04 0.14 ± 0.01 0.06 ± 0.01
0.5 0.68 ± 0.03 0.41 ± 0.04 0.15 ± 0.01 0.06 ± 0.01
0.55 0.71 ± 0.02 0.37 ± 0.03 0.16 ± 0.02 0.06 ± 0.01
0.6 0.72 ± 0.02 0.33 ± 0.03 0.18 ± 0.02 0.06 ± 0.01
0.65 0.75 ± 0.02 0.27 ± 0.03 0.21 ± 0.02 0.06 ± 0.01
0.7 0.76 ± 0.02 0.24 ± 0.03 0.23 ± 0.02 0.05 ± 0.01
0.75 0.76 ± 0.02 0.22 ± 0.03 0.24 ± 0.02 0.05 ± 0.01
0.8 0.76 ± 0.02 0.18 ± 0.02 0.27 ± 0.02 0.05 ± 0.01
0.85 0.76 ± 0.02 0.15 ± 0.02 0.30 ± 0.02 0.05 ± 0.01
0.9 0.74 ± 0.02 0.09 ± 0.01 0.37 ± 0.02 0.06 ± 0.01
0.95 0.69 ± 0.02 0.06 ± 0.01 0.44 ± 0.02 0.07 ± 0.01
Results presented as mean values ± standard deviation. Legend: SI = Similarity Index; FPR = False positive rate;
FNR = False negative rate; DER = Detection error rate.
3.2.4 BIANCA algorithm improvement
After optimising the input data and threshold cut-offs, other parameters were manipulated to
improve the performance of BIANCA. Algorithm performance improvement was pursued with in-
clusion of additional considerations for spatial weighting (sw) and patch size. Sw uses spatial data
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to give different weightings to specific voxels dependant on their position and hence the likelihood
of being a WMH. The default sw = 1, so an increase in sw will have a larger effect on voxels deemed
to be in a position likely to be a WMH. Sw values of 2 and 3 were included in the improvement
investigation. A patch in the BIANCA call is an option based on the intensity data of a voxel. By
classifying voxels based on neighbourhoods of voxels equal to the patch size instead of individually
the algorithm is less prone to voxel false positive and false negative detection [19]. Patch sizes of
3, 4, and 9 were tested.
An exclusion mask applied to the BIANCA output mask so that the output only included hyper-
intensities that appear in WM, which potentially reduces the number of false positives detected.
BIANCA has a built-in exclusion mask creation script that excludes cortical GM and a number of
sub-cortical nuclei and structures from the algorithm output. Alternatively, an input image can
be masked before the algorithm is run so that only WM is included, eliminating the possibility of
identification of hyperintensities outside the WM. Both masking options were trialed in the algo-
rithm improvement testing.
Another improvement technique included using bias-corrected input images. Bias correction refers
to the elimination of low-frequency signal produced by the MRI machine during image acquisition.
This makes contrast across the images more consistent which is vital for an algorithm using voxel
intensity to determine classification [25].
Additionally, 10 low burden and 10 high burden subjects were added to the training set to increase
the amount of data available for training the algorithms. The inclusion of low burden training
subjects was tested since it would introduce learning instances for low burden subjects, thus limit-
ing overestimation of the algorithm trained solely on high burden subjects where large volumes of
WMHs were consistent across training data but not representative of the entire cohort.
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3.2.5 Improved BIANCA results
sw = 2, 3 and patch = 2, 3, 4, 9 were added to the original BIANCA call individually and in con-
junction, and the combination sw = 2 and patch = 3 was found to improve the original BIANCA
with only a marginal increase in the mean SI value, and was therefore not included in subsequent
optimisation steps.
Assessment of the improvement made by increased training subjects, inclusion masks, and bias-
corrected input images were combined. I found that increasing the training set by all 20 additional
subjects improved the performance more than just including the 10 low burden additional subjects.
The optimised performance of BIANCA was achieved when using bias-corrected input images in
FLAIR space using 40 training subjects with no sw or patch. The BIANCA output mask was cal-
culated with a threshold = 0.8, and a WM inclusion mask was applied to the BIANCA output. The
mean dice coefficient calculated under these training specifications was SI = 0.80±0.01 (Table 3.3).
Table 3.3: Improved BIANCA outputs, optimal post-processing threshold reported for each trial
only. Optimal performance is indicated in bold.
Training specification SI Voxel FPR Voxel FNR DER Threshold
20 0.76 ± 0.02 0.18 ± 0.02 0.27 ± 0.02 0.05 ± 0.01 0.8
30 (low burden) 0.76 ± 0.01 0.18 ± 0.02 0.27 ± 0.02 0.06 ± 0.01 0.85
40 0.77 ± 0.01 0.21 ± 0.02 0.22 ± 0.02 0.05 ± 0.01 0.8
40 (BC) 0.80 ± 0.01 0.19 ± 0.02 0.19 ± 0.01 0.03 ± 0.00 0.85
40 (BC, masked output) 0.80 ± 0.01 0.16 ± 0.02 0.21 ± 0.01 0.03 ± 0.00 0.8
40 (BC, masked FLAIR input) 0.80 ± 0.01 0.17 ± 0.02 0.21 ± 0.01 0.03 ± 0.00 0.8
Results presented as mean values ± standard deviation. Legend: SI = Similarity Index; FPR = False positive rate;
FNR = False negative rate; DER = Detection error rate; BC = Bias-corrected.
3.2.5.1 BIANCA results comparison to literature
My optimised BIANCA performance on the training data set was compared to published literature.
Firstly, comparison to the results in Griffanti et al. (2016) showed that the optimised parameters for
BIANCA (with bias-corrected images in FLAIR space and a post-processing WM inclusion mask)
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outperformed the metrics of BIANCA on both published data sets with SIs of 0.76 and 0.52 [19]. A
paper by Ling et al. (2018) optimised BIANCA for two datasets (n=90, 66) and the performance
measures achieved, SI = 0.79 and SI = 0.80 respectively, are comparable to our performance
measures [30]. Thus, the optimised BIANCA algorithm here was approximately equivalent to the
high performance reported in other disease cohorts.
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3.3 Lesion Growth Algorithm: LGA
3.3.1 LGA algorithm overview
Lesion Growth Algorithm (LGA) is an unsupervised classification algorithm in the Lesion Segment-
ing Toolbox (LST) toolbox for SPM. The toolbox provides an automated method of identifying
WMHs originally created for use in Multiple Sclerosis (MS). LGA requires inputs of raw T1 and
T2 FLAIR images, and only the initial threshold, κ, need be selected.
LGA operates in T1 space, and can essentially be broken into 3 steps. In the pre-processing step,
the T1 image is segmented into grey matter (GM), WM, and cerebrospinal fluid (CSF). The FLAIR
image is bias-corrected and registered to T1 space along with a standard SPM WM probability map.
In the second step, lesion belief maps for the 3 tissues are created by identifying hyperintensities
based on FLAIR voxel intensity and spatial location. These initial lesion belief maps are summed,
B = b1, . . . , bn, and the GM belief map, BGM , is used to create a seed for the lesion mask to grow, as
increasing voxel values of BGM indicate that the voxel is more likely to be included in a WM lesion
(see Schmidt et al., (2012) section ‘Lesion belief maps and initialization’ for detail). The value of an
individual voxel i in the GM belief map, bGM,i, is used to determine the class of the corresponding
individual voxel in the initial lesion map, linit,i, by equation 3.5. Hence Linit,1 = linit,1, ..., linit,i is
the binary map used to initiate the iterative growth of the WMH map.
linit,i = 1 −→← bGM,i > κ (3.5)
The third step grows Linit,i towards B via an iterative process. The algorithm identifies voxels
adjacent to any voxel included in Linit,1 and tests it to either accept or reject the voxel under
consideration from the growing lesion map. The adjacent voxel under consideration is assigned a
probability value of being a lesion voxel with considerations for size and shape of gamma distribution
describing the lesion map and utilises a Markov random field (MRF) to assure the probabilistic
value assigned to the voxel of interest depends only on labelled voxels in its neighbourhood. The
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voxel is assigned a probability value according to the equation 3.6:
πLesi = Pr(zi = Les) = min
(
1,










Here, Ni is the first order neighbourhood of the voxel of interest, i, wherein there is at least one
voxel, j that has a lesion probability πLesj > 0, jεNi. yi is the normalised FLAIR intensity of i.
Pr(zi = Les) is the probability value of the voxel belonging to the lesion map. PLes is the gamma
distribution density function for the lesion class with parameters α for size and β for shape. Pother
is the combined GM, WM, CSF Gaussian distribution. The iterative process will halt when the
preset maximum number of iterations is reached or the largest new lesion probability is < 0.01.
More thorough details of this algorithm are provided in the 2012 paper by Schmidt et al. [47].
3.3.2 Initial LGA results
LGA v 2.0.15 was used in this study. Initial values of κ = 0.10, 0.25, 0.30, 0.35, 0.40 were investi-
gated and inputs of raw T1 and FLAIR were used. As with BIANCA, LGA output masks were
compared to the manual masks based on the defined performance measures. The LGA probability
maps were in T1 space, thus needed to be registered to FLAIR space to calculate the equivalent
algorithm performance measures, and FSL FLIRT was used to register the WMH probability maps
to FLAIR space. Thresholds between 0-1 were then used to assess algorithm performance, and a
post-processing threshold = 0.05 was found to consistently be the threshold that resulted in the
highest SI value across all κ values; this threshold was used to compare the different iterations of
the algorithm. κ = 0.1 was the best value to use, and resulted in SI = 0.63± 0.02 (Table 3.4).
3.3.3 LGA algorithm improvement and results
An attempt to improve the performance of LGA involved coregistering the raw T1 image to FLAIR
space for the T1 input. Again, a threshold value = 0.1 resulted in the highest SI, however, the
results did not outperform the original raw T1 input images (Table 3.5). The coregistration of the
T1 image was successful for all training subjects, however, LGA did not work on one subject after
the coregistration of input images. This subject was excluded from the subsequent calculation of
performance measures of LGA using coregistared T1 images.
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Table 3.4: LGA results: Input of raw FLAIR and T1 images calculated in FLAIR space. Optimal
performance is indicated in bold.
κ SI Voxel FPR Voxel FNR DER
0.10 0.63 ± 0.02 0.20 ± 0.02 0.47 ± 0.03 0.11 ± 0.02
0.25 0.59 ± 0.02 0.13 ± 0.02 0.54 ± 0.03 0.11 ± 0.02
0.30 0.57 ± 0.03 0.12 ± 0.02 0.57 ± 0.03 0.11 ± 0.02
0.35 0.55 ± 0.03 0.12 ± 0.02 0.59 ± 0.03 0.12 ± 0.03
0.40 0.53 ± 0.03 0.11 ± 0.02 0.61 ± 0.03 0.12 ± 0.03
Results presented as mean values ± standard deviation. Legend: SI = Similarity Index; FPR = False positive rate;
FNR = False negative rate; DER = Detection error rate; κ = parameter determining how conservative initial lesion
map.
Table 3.5: LGA test results presenting input images of raw FLAIR and coregistered T1. Perfor-
mance measures calculated in FLAIR space. Optimal performance is indicated in bold.
κ SI Voxel FPR Voxel FNR DER
0.05 0.60 ± 0.03 0.16 ± 0.03 0.53 ± 0.03 0.12 ± 0.03
0.10 0.59 ± 0.03 0.10 ± 0.02 0.55 ± 0.03 0.10 ± 0.02
0.25 0.53 ± 0.03 0.06 ± 0.01 0.63 ± 0.03 0.12 ± 0.03
0.30 0.51 ± 0.03 0.05 ± 0.01 0.65 ± 0.03 0.13 ± 0.03
Results presented as mean values ± standard deviation. Legend: SI = Similarity Index; FPR = False positive rate;
FNR = False negative rate; DER = Detection error rate; κ = parameter determining how conservative initial lesion
map.
The number of maximum iterations was also increased from 50 to 150 as some subjects map growths
were stopped since they reached 50 iterations instead of reaching a point where the probability
values of all voxels dropped below 0.01. These alterations of LGA improved the FPR detection,
however, consideration must be given to the fact that only 19 of 20 subjects could be used to
calculate the performance measures. With this considered, the original result of LGA performance
using κ = 0.1 and raw T1 and FLAIR T2 input images was used as the optimal performance of the
algorithm, and used for comparison to the other tested algorithms.
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Table 3.6: LGA similarity index comparison to literature values. Optimal performance is indicated
in bold.
Paper κ Training Subjects SI
Our results 0.1 20 PD 0.63
Schmidt et al. (2012) 0.3 53 MS 0.75
Griffanti et al. (2016) 0.2 85 AD 0.69
Rachmadi et al. (2017) 0.13 20 AD 0.30
Legend: SI = Similarity index; PD = Parkinson’s disease; AD = Alzheimer’s disease; MS = Multiple sclerosis; κ =
parameter determining how conservative initial lesion map.
3.3.3.1 LGA result comparison to literature
The performance of LGA in our training data set was inconsistent with the literature published for
other studies which reported a range of SIs. In the 2012 paper by Schmidt et al. where this method
was first presented, the average SI for a cohort of 53 MS patients was SI = 0.75 when using a value
of κ = 0.3 [47]. The 2016 paper by Griffanti et al. reported SI = 0.69 at κ = 0.2 when used on a
cohort of 85 individuals with AD [19]. A more recent paper by Rachmadi et al., 2017 reported an
average SI of 0.29 at κ = 0.13 on an AD cohort of 20 [39]. These results have been tabulated in
Table 3.6. This variation in SI across studies may be due to the inherent differences between the
sampled studies, such as the cohorts used in terms of the number of patients and cohort disease,
and the inconsistencies in the MR images chiefly caused by different acquisition machines and MRI
protocols. All of these factors could have impacted the performance of LGA and the resultant SI
values calculated.
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3.4 Lesion Probability Algorithm: LPA
3.4.1 LPA algorithm overview
Lesion Probability Algorithm (LPA) is a supervised classification lesion segmenting algorithm in
the LST toolbox v 2.0.15 of SPM. LPA uses LGA and its default settings, as detailed above in 3.3.1,
to estimate the location of the WM lesions and then applies this learned information to different
study cohorts. LPA uses prior WMH knowledge as determined by LGA trained using a cohort of 53
MS patients with high WMH burden, a total lesion volume (TVL) > 10 ml, and lesion probability
maps for each training individual are calculated. The only inputs required for LPA are T2-weighted
FLAIR images since the inclusion of T1-weighted image is only needed for the creation of reference
lesion maps in LGA, which has already been completed in the (independent) MS training cohort.
LPA first runs a bias correction step on the FLAIR images to regulate the intensity features of the
images. Then lesion probability maps are created iteratively in the same way as LGA except the
reference lesion maps are calculate by LGA in the training cohort instead of per subject within
the cohort of interest. LPA produces the linear predictor, η̂i, by combining posterior means as in
equation 3.7, wherein β0 is the intercept, xi is the lesion belief map for the ith voxel, β1 is the effect
of the lesion belief map, and γi models the spatial effect.
η̂i = β̂0 + β̂1xi + γ̂i (3.7)





There is a post-processing step included in LPA that removes any positively identified WMH if it is
< 0.015ml in volume. LPA reportedly works well with FLAIR input alone as additional modality
images require additional pre-processing of coregistration to the same, space which is subject to
error, particularly for subjects with high WMH burden [46].
More detail on LPA can be found in the 2017 thesis by Schmidt et al. [46].
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3.4.2 LPA data preparation
LPA requires only the FLAIR image input and needs no initial parameters selected. Additionally,
there is an option of adding reference images (structural T1-weighted) to the input data. LPA
was therefore trialled both with and without reference images. Coregistration of input images only
occurs when a T1 image is included in the algorithm input. The output of LPA is a non-binary
lesion probability map that required thresholding to produce a binary WMH mask. A range of
threshold values between 0-1 were tested to find the best one for use in the training data set (i.e.
highest SI to the study ‘gold-standard’ manual masks).
3.4.3 LPA results
LPA performed better when only a FLAIR image was used as the input image, perhaps due to
the coregistration error highlighted by Schmidt et al. [46]. The highest SI value achieved by LPA
was SI = 0.67 ± 0.03 when the LPA output mask was calculated at a post-processing threshold
= 0.35. In terms of improving LPA’s performance, bias-corrected inputs were not considered for
improvement of LPA because a bias correction is included in the algorithm. There is no training
data input required for the algorithm, so increasing the test inputs from 20 to 40 was unnecessary
for LPA.
When FLAIR was the only image input, the LPA probability maps are produced in FLAIR space.
When T1 images were included as the input and coregistration occurred, the LPA probability maps
are produced in T1 space. In the latter case, the probability maps were registered to FLAIR space
using FSL FLIRT for performance measure calculation.
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Table 3.7: LPA test results at different post-processing thresholds. Results presented for trial
exclusively using FLAIR images, and FLAIR and T1-weighted images. Optimal performance is
indicated in bold.
Threshold SI Voxel FNR Voxel FPR DER
0.05 FLAIR only 0.61 ± 0.04 0.45 ± 0.06 0.16 ± 0.02 0.06 ± 0.01
0.1 FLAIR only 0.62 ± 0.04 0.44 ± 0.06 0.17 ± 0.02 0.07 ± 0.02
0.15 FLAIR only 0.63 ± 0.04 0.41 ± 0.06 0.18 ± 0.02 0.07 ± 0.02
0.2 FLAIR only 0.65 ± 0.04 0.38 ± 0.05 0.20 ± 0.02 0.07 ± 0.02
0.25 FLAIR only 0.67 ± 0.03 0.35 ± 0.05 0.23 ± 0.02 0.07 ± 0.02
0.3 FLAIR only 0.67 ± 0.03 0.33 ± 0.05 0.25 ± 0.02 0.07 ± 0.02
0.35 FLAIR only 0.67 ± 0.03 0.30 ± 0.05 0.27 ± 0.03 0.08 ± 0.02
0.4 FLAIR only 0.67 ± 0.03 0.28 ± 0.05 0.30 ± 0.03 0.08 ± 0.02
0.45 FLAIR only 0.67 ± 0.03 0.26 ± 0.05 0.33 ± 0.03 0.08 ± 0.02
0.5 FLAIR only 0.66 ± 0.03 0.24 ± 0.05 0.35 ± 0.03 0.08 ± 0.02
0.55 FLAIR only 0.66 ± 0.02 0.22 ± 0.05 0.38 ± 0.03 0.08 ± 0.02
0.6 FLAIR only 0.64 ± 0.02 0.20 ± 0.05 0.42 ± 0.03 0.09 ± 0.01
0.65 FLAIR only 0.62 ± 0.02 0.19 ± 0.05 0.46 ± 0.03 0.09 ± 0.01
0.7 FLAIR only 0.59 ± 0.03 0.15 ± 0.04 0.51 ± 0.03 0.10 ± 0.02
0.75 FLAIR only 0.55 ± 0.03 0.14 ± 0.04 0.56 ± 0.03 0.12 ± 0.03
0.8 FLAIR only 0.50 ± 0.03 0.12 ± 0.04 0.63 ± 0.03 0.13 ± 0.03
0.85 FLAIR only 0.37 ± 0.03 0.08 ± 0.03 0.76 ± 0.02 0.14 ± 0.03
0.9 FLAIR only 0.30 ± 0.02 0.06 ± 0.02 0.82 ± 0.02 0.15 ± 0.04
0.95 FLAIR only 0.23 ± 0.02 0.04 ± 0.02 0.87 ± 0.02 0.16 ± 0.04
0.05 FLAIR and T1 0.34 ± 0.04 0.70 ± 0.03 0.57 ± 0.04 0.11 ± 0.03
0.1 FLAIR and T1 0.34 ± 0.04 0.68 ± 0.04 0.60 ± 0.04 0.12 ± 0.04
0.15 FLAIR and T1 0.34 ± 0.04 0.67 ± 0.04 0.62 ± 0.04 0.13 ± 0.04
0.2 FLAIR and T1 0.34 ± 0.04 0.66 ± 0.04 0.64 ± 0.04 0.13 ± 0.04
0.25 FLAIR and T1 0.34 ± 0.04 0.65 ± 0.04 0.65 ± 0.04 0.14 ± 0.04
0.3 FLAIR and T1 0.33 ± 0.04 0.64 ± 0.04 0.67 ± 0.04 0.14 ± 0.04
0.35 FLAIR and T1 0.33 ± 0.04 0.63 ± 0.04 0.68 ± 0.04 0.14 ± 0.04
0.4 FLAIR and T1 0.33 ± 0.04 0.62 ± 0.04 0.70 ± 0.04 0.14 ± 0.04
0.45 FLAIR and T1 0.32 ± 0.04 0.61 ± 0.05 0.71 ± 0.03 0.14 ± 0.04
0.5 FLAIR and T1 0.32 ± 0.04 0.60 ± 0.05 0.72 ± 0.03 0.14 ± 0.04
0.55 FLAIR and T1 0.31 ± 0.04 0.59 ± 0.05 0.74 ± 0.03 0.14 ± 0.03
0.6 FLAIR and T1 0.30 ± 0.04 0.59 ± 0.05 0.75 ± 0.03 0.14 ± 0.03
0.65 FLAIR and T1 0.29 ± 0.04 0.58 ± 0.05 0.77 ± 0.03 0.14 ± 0.03
0.7 FLAIR and T1 0.28 ± 0.03 0.57 ± 0.05 0.78 ± 0.03 0.15 ± 0.04
0.75 FLAIR and T1 0.27 ± 0.03 0.56 ± 0.05 0.80 ± 0.03 0.15 ± 0.04
0.8 FLAIR and T1 0.25 ± 0.03 0.55 ± 0.05 0.82 ± 0.02 0.16 ± 0.04
0.85 FLAIR and T1 0.23 ± 0.03 0.55 ± 0.05 0.84 ± 0.02 0.17 ± 0.04
0.9 FLAIR and T1 0.21 ± 0.03 0.54 ± 0.05 0.86 ± 0.02 0.17 ± 0.04
0.95 FLAIR and T1 0.17 ± 0.03 0.53 ± 0.06 0.90 ± 0.02 0.20 ± 0.06
Results presented as mean values ± standard deviation. Legend: SI = Similarity Index; FPR = False positive rate;
FNR = False negative rate; DER = Detection error rate.32
3.5 Unidentified Bright Object Detector: UBO Detector
3.5.1 UBO Detector algorithm overview
UBO Detector is the most recent detection algorithm that was tested, being developed and released
in 2017 by Jiang and colleagues [23]. UBO is a fully automated, supervised detection method that
uses a combination of SPM tools for segmentation and registration and a k-NN algorithm to identify
WMHs. There is a built-in post-processing step in which the global WMHs are further separated
into regional WMHs; namely periventricular WMHs (PVWMHs), deep WMH (DWMH), and lobar
and arterial regional WMHs. UBO Detector is unique to the other algorithms tested as it operates
standardised (normalised or MNI) space.
3.5.1.1 Pre-processing
UBO takes inputs of raw FLAIR images and corregisters them to the higher resolution T1-weighted
images. Tissue class probability maps (GM, WM, and CSF) are generated by segmentation of the
T1-weighted images. DARTEL (Diffeomorphic Anatomical Registration Through Exponentiated
Lie) is then run on the original T1-weighted image creating a subject-specific warp flow field that
can be used then to register the tissue class probability maps and FLAIR images to normalised
space also. This is followed by bias correction of the normalised FLAIR image. Non-brain tissues
are then removed in normalised space before FSL FAST is run on the normalised FLAIR image to
segment GM, WM, and CSF to effectively identify clusters of interest for WMH identification.
3.5.1.2 WMH extraction
k-NN, as described in Section 3.2.1, is then applied to the images in MNI (normalised) space, with
k = 5, the default k-value. The training data used for UBO Detector consisted of 10 individuals
in the Sydney Memory and Ageing Study (Sydney MAS), and true positive WMHs were chosen
by visually assessing FAST extraction on the training set by Jiang et al. [24]. UBO Detector
also offers the option of including study-specific training data to create a classification model that
potentially better suited to the data set in use. The outputs of the k-NN algorithm are improved
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by the inclusion of intensity and spatial location values, as detailed in the 2018 paper by Jiang et
al. [24]. WMH probability maps are then created from the k-NN algorithm output using these
intensity and spatial features.
3.5.1.3 Post-processing
The built-in post-processing separates the global WMH map output into sub-regions by two meth-
ods. Firstly, PVWMHs, DWMHs, and lobes are separated by a distance map method in which
WMH detected within 12mm around the ventricles are identified as PVWMHs. Any WMHs that
lie outside this 12mm mask, ie non-PVWMHs, are then further separated into lobes such that all
WMHs identified by UBO Detector can be specifically categorised. UBO Detector is an appealing
choice of WMH detector due to this additional post-processing step of segmenting the output masks
due to our future interest in the WMH burden of distinct brain areas and lobes.
Further detail of UBO Detector can be found in the 2018 paper by Jiang et al. [24].
3.5.2 UBO Detector initial results
As mentioned above, UBO Detector can be run with the default parameters, or these can also be
changed to better suit the cohort being segmented by creating a custom classifier. Optimised pa-
rameters for the built-in k-NN classifier were determined by a LOO cross-validation method on the
built-in MS training data set [24]. Initially, UBO Detector was run with the recommended settings
of k = 5 and a post-processing threshold = 0.7. Assessment of similarity measures were calculated
using the binary FLAIR space mask output for consistency with the other algorithms opposed to
in normalised space. Using the default algorithm settings, SI = 0.61±0.02 was achieved, see Table
3.8 for all performance measures.
3.5.3 UBO Detector algorithm improvement
There were a series of improvements that were tested on UBO Detector that followed from the
improvements made with BIANCA. Using the custom classifier, increasing the training data to 40
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subjects, and using bias-corrected input images were all pursued for improvement in performance
for the same reasons as in Section 3.2.4.
3.5.4 UBO Detector improved results
The results of all the trials of UBO detector are presented in Table 3.8 with the highest SI value
produced by using bias-corrected input FLAIR and T1-weighted images for 40 training subject
using a custom classifier (Table 3.8).
Table 3.8: UBO test results. Optimal performance is indicated in bold.
Trial SI Voxel FNR Voxel FPR DER
20 Training, built-in classifier 0.61 ± 0.02 0.12 ± 0.02 0.52 ± 0.02 0.08 ± 0.02
20 Training, custom classifier 0.53 ± 0.04 0.08 ± 0.01 0.60 ± 0.04 0.23 ± 0.07
40 Training, custom classifier 0.64 ± 0.02 0.36 ± 0.03 0.34 ± 0.02 0.08 ± 0.01
40 Training, custom classifier, bias-corrected 0.66 ± 0.02 0.34 ± 0.02 0.31 ± 0.02 0.08 ± 0.01
Results presented as mean values ± standard deviation. Legend: SI = Similarity Index; FPR = False positive rate;
FNR = False negative rate; DER = Detection error rate.
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3.6 Algorithm selection and justification
In the training data, BIANCA was the WMH detection method that exhibited the strongest perfor-
mance, with individual optimised algorithm performance for the four algorithms tested as follows;
BIANCA SI = 0.80 ± 0.01; LGA SI = 0.63 ± 0.02; LPA SI = 0.67 ± 0.03; UBO Detector SI
= 0.66 ± 0.02. The performance of BIANCA resulted in an SI comparable to those quoted in the
reviewed literature. Similarly, BIANCA consistently proved the highest SIs across the 4 methods
trialled, even before improvement steps were taken.
It is important to note that due to their nature, LGA and LPA posed fewer options for improve-
ment as the inputs and initial parameters are limited. BIANCA and UBO Detector offer more
opportunity to train the algorithm to the specific cohort being used. BIANCA also resulted in
the best performance measures across all 4 algorithms even before any study-specific improvements
had been made, and BIANCA resulted in the highest SI on an individual subject level across all
training subjects and all algorithms. For these reasons, BIANCA was selected and applied to the
entire cohort, using optimised algorithm parameters.
Increasing the size of the training data set was one of the major improvement technique, specifically
by including low WMH burden training subjects. The training data set was increased to explicitly
include low WMH burden subjects to remedy overestimation of the algorithm when applied to the
entire set of MRI scans being used in this study. Overestimation manifest in the algorithm output
masks as a large number of small false positive ‘speckles’ throughout the volume of the brain, es-
pecially in and close to cortical regions. It became clear that the inclusion of low WMH burden
training subjects did not improve the performance of the algorithms as the overestimation persisted
after the training cohort was increased. The overestimation was therefore removed by applying a
threshold for very small lesions that were too small to be considered true positives, details of this
follow in Chapter 4.
Bias-corrected input images were much more successful in improving the resultant algorithm out-
put masks compared to the increase in the number of training subjects. The bias-corrected images
36
improved contrast levels between different tissue types, as well as between healthy and pathological
WM. Improved contrast levels resulted in more successful k-NN algorithm WMH identification due
to the nature of the algorithm and its use of voxel intensity. Testing the improvement of algorithm
performance using increased training data set size and using bias-corrected images demonstrated






Figure 3.1: Representative FLAIR image of training subjects and results from 4 optimised algo-
rithms. (a) Bias-corrected FLAIR image. (b)Manual mask. (c) BIANCA: Bias-corrected input
images, FLAIR space, 40 training subjects, threshold = 0.80, SI = 0.82. (d) LGA: Raw T1 and
FLAIR, κ = 0.1, threshold = 0.05, SI = 0.55. (e) LPA: FLAIR only, threshold = 0.35, SI = 0.76.




Study specifications and analysis
methods
This chapter presents the full longitudinal PD cohort and the analytical techniques used to investi-
gate the relationship in question between WMHs and cognitive impairment in PD. The analysis that
follows from this point uses the WMH masks produced by BIANCA using the optimal parameters
and inputs determined in Chapter 3 applied to the full cohort.
4.1 Cohort
The data utilised in this study was a subset of the data in an ongoing longitudinal study that began
in May 2007. Study participants were recruited from the Movement Disorders Clinic at the New
Zealand Brain Research Institute, Christchurch, New Zealand. The longitudinal cohort utilised in
this thesis comprised 232 participants meeting the UK Parkinson’s Disease Society’s criteria for
idiopathic PD, with participants representative of the broad spectrum of cognitive impairment in
PD. The control group was made up of 64 healthy volunteers who were matched to the average
characteristics of PD participants, including age, sex ratio, and years of education.
Participants were assessed at baseline and had follow-up assessments approximately every two years
after baseline, completing a rigorous neuropsychological battery, clinical assessment, and 3 T MRI
scanning at each assessment. Exclusion criteria for this cohort included atypical Parkinsonian
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Table 4.1: Study subjects at baseline
Cognitive group Control PD-N PD-MCI PDD ANOVA Overall p-value Pairwise comparison (Tukey HSD) > / <∼< 0.05
Baseline n 49 81 71 27
Sex baseline (F:M) 16:33 29:52 17:54 4:23
Mean age baseline 69.3 (8.4) 65.1 (8.0) 71.4 (6.5) 74.7 (6.3) e F (3, 224) = 15.1 < 0.001 HC > PD-N < PD-MCI ∼ PDD
Education years baseline 13.4 (2.8) 13.0 (2.7) 12.6 (3.0) 12.4 (2.4) F (3, 224) = 1.2 = 0.329 HC ∼ PD −N ∼ PD −MCI ∼ PDD
Cognitive z score baseline 0.59 (0.39) 0.21 (0.44) -0.86 (0.47) -1.83 (0.52) F (3, 224) = 241.1 < 0.001 HC > PD −N > PD −MCI > PDD
MoCA score baseline 26.9 (2.1) 26.5 (2.2) 22.7 (3.1) 16.8 (3.6) F (3, 221) = 111.7 < 0.001 HC > PD −N > PD −MCI > PDD
Executive function domain baseline 0.62 (0.52) 0.32 (0.30) -1.00 (0.72) -2.02 (0.50) F (3, 224) = 165.0 < 0.001 HC > PD −N > PD −MCI > PDD
Attention domain baseline 0.32 (0.49) 0.05 (0.47) -0.97 (0.53) -1.94 (0.61) F (3, 224) = 162.6 < 0.001 HC > PD −N > PD −MCI > PDD
Memory domain baseline 0.89 (0.77) 0.26 (0.80) -0.89 (0.71) -1.74 (0.72) F (3, 224) = 101.9 < 0.001 HC > PD −N > PD −MCI > PDD
Visuospatial domain baseline 0.53 (0.55) 0.22 (0.50) -0.58 (0.72) -1.63 (0.75) F (3, 224) = 91.5 < 0.001 HC > PD −N > PD −MCI > PDD
Baseline study subject data, with details for each cognitive domain. Data presented as mean(SD)
or ratios.
HC = Healthy control; PD-N = Parkinson’s disease normal cognition; PD-MCI = Parkinson’s disease mild cognitive
impairment; PDD = Parkinson’s disease dementia; MoCA = Montreal Cognitive Assessment.
disorder, prior learning disability, history of other neurological conditions (moderate-severe head
injury, stroke, vascular dementia, major psychiatric or medical illness in the previous 6 months).
Baseline MRI screening excluded subjects presenting significant non-PD pathology, including one
control and three PD for severe WM disease, one PD for marked cerebral atrophy, one control for
arachnoid cyst and chronic inflammatory demyelinating polyneuropathy, one control for cerebellar
infarcts, and one PD for cortical infarcts. Three PD were excluded due to motion artefacts across
all MR images, and three controls were excluded for meeting criteria for MCI.
Over the duration of the study, three PD subjects had cortical stroke, one PD subject was di-
agnosed as progressive supranuclear palsy (PSP) and one PD subject was diagnosed as multiple
system atrophy (MSA). All data from those participants re-classified as having an atypical parkin-
sonian disorder were excluded, while images taken prior to stroke were included. The final cohort
analysed in this thesis, therefore, included 207 PD and 51 Control participants that completed at
least one MRI and associated cognitive testing session. A total of 585 MRI scans collected over
the duration of the longitudinal study were utilised in this study, with a total of 217 PD-N, 168
PD-MCI, 42 PDD, and 158 control scans analysed, Table 4.1 provides details of these subjects.
The study was approved by the regional Ethics Committee of the New Zealand Ministry of Health.
All participants were given written, informed consent, with additional consent from a significant
other when appropriate.
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4.2 Cognitive diagnostic criteria and assessment
Comprehensive cognitive testing consistent with Movement Disorder Society Task Force level II
criteria for the diagnosis of MCI was carried out, per Wood et al. (2016) [59]. PDD diagnosis was
also defined by the Movement Disorders (MDS) Task Force criteria [14]. The cognitive test battery
included at least two tests within 5 cognitive domains; executive function, attention and working
memory, learning and memory, visuospatial performance and language. Table 4.2 presents these
tests [13, 59]. PD-MCI was diagnosed when the patient’s functional activities in daily life were
unimpaired, but their cognitive scores were 1.5 SDs or more below normative data in at least two
tests of at least one of the assessed cognitive domains, excluding language (language was excluded
due to low variance). Global cognitive performance was quantified by an aggregate z score derived
from the mean of the average standardised scores in the four cognitive domains listed above, ex-
cluding language. Additional cognitive tests included the Montreal Cognitive Assessment (MoCA),
the Dementia Rating Scale (MDRS-2), and the Alzheimer’s Disease Assessment Scale Cognition
(ADAS-Cog) tests. Functional and psychiatric status was assessed with Instrumental Activities
of Daily Living, Clinical Dementia Rating (CDR) status, Global Deterioration Scale, Parkinson’s
Disease Questionnaire (PDQ-39), Neuropsychiatric Inventory (NPI), and the Geriatric Depression
Scale [2].
For brevity, for the remainder of this thesis, I will refer to the learning and memory domain as the
memory domain, and the attention, working memory, and processing speed domain as the attention
domain.
4.3 MRI acquisition
All images were acquired using a 3 T General Electric HDxt scanner with an eight-channel head
coil. Structural MR images were obtained according to the following specifications;
T1-weighted 3D spoiled gradient recall echo (SPGE), TE/TR = 2.8/6.6 ms, TI=400 ms, flip
angle=15◦, acquisition matrix=256×256×170, FOV=250 mm, slice thickness=1 mm, voxel size=0.98×0.98×1.0
mm3.
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T2-weighted FLAIR PROPELLOR (motion insensitive radial k-space) 2D, TE/TR =
105/9000 ms, TI =2250 ms, echo train length=36, acquisition matrix=320×320×35, FOV=220
mm, slice thickness=3mm, gap=1.5 mm, reconstruction voxel size=0.43×0.43×4.5 mm3.
4.4 Application of BIANCA
As discussed in Chapter 3, of the tested algorithms BIANCA produced the best performance
metrics. Thus BIANCA with optimised parameters was used to create probabilistic WMH lesion
masks in all study participants at each time point.
4.5 BIANCA output mask normalisation
Normalisation of the WMH output probability maps from BIANCA WMH masks was carried
out by warping images in subject space to a standardised template space (in this thesis, I used
the DARTEL MNI template available with CAT12). The normalisation process attempts to re-
move differences in brain size and shape of an individual, while at the same time maintaining
subject-specific features. Normalisation of all BIANCA WMH maps was based on the deformation
parameters derived from normalising the registered T1-weighted images; normalisation was carried
out using CAT12, a toolbox of SPM12 (Section 4.6.1).
The data in this study were analysed both cross-sectionally and longitudinally. Therefore, I per-
formed two different processing streams, presented below.
4.5.1 FLAIR space to T1 space
The first step in normalisation of BIANCA WMH masks for longitudinal and cross-sectional data
is the removal of small, false positive clusters from the binary FLAIR output mask. Clusters of 10
voxels or smaller were eliminated from the masks as clusters under this size most likely represent
false positive WMHs [57]. A cluster limit of 10 voxels was selected following the work of Wahlund
et al., in which 5 mm diameter WMHs were stated to be false positive. 10 voxels in the FLAIR im-




























































































































































































































































































































































































































































































































































































































was chosen to ensure no true positive clusters would be removed from the BIANCA output masks.
This is a trade-off between removing false positive WMHs and ensuring no true positive WMHs
are removed in the process.
After false positive clusters were removed, the BIANCA WMH masks were coregistered to the
T1 space. The T2 FLAIR images were coregistared to the T1 images using SPM12’s Coregister:
Estimate and Reslice, which is used for intra-subject registration with rigid-body model and reslic-
ing. Coregister: Estimate and Reslice includes a smoothing step to reduce the change of local
maxima in the coregistered image, increase convergence time, and smooths the cost function as
much as possible (spm12/man/manual.pdf). The coregistration tool uses the T1-weighted image
as a reference, the T2-weighted FLAIR image as the source image (the image which is reoriented
to match the reference image), and the BIANCA WMH mask in FLAIR space is an additional
image which is coregistared along with the T2 FLAIR. All other parameters used are the standard
default settings. The coregistration assured that the WMH masks were aligned to T1 space, which
then allowed application of the structurally-derived deformation fields to warp WMH masks into
normalised space (described in Section 4.6.2).
4.5.2 Longitudinal average T1 images
At this point, the normalisation process differs slightly for longitudinal and cross-sectional data
with the longitudinal data requiring an additional processing step. The longitudinal data process-
ing must account for multiple scans of the same individual at various time points, and so requires
within-subject registration step or T1 averaging step (i.e., the creation of a within-subject average
T1 template creation). Subjects that had only one scan over all time points did not require this
within-subject registration step.
To account for the multiple time points of the same subjects in longitudinal data, average T1 images
were calculated for every subject with 2 or more scans. Average T1 images were calculated using
SPM12 Serial Longitudinal Registration with default parameters. To avoid any bias introduced by
averaging the multiple scan subjects, I also created a ‘pseudo-average’ for participants with only a
single scan. To do this, T1 images were flipped left-to-right; the original and flipped images were
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then registered and an average image created (Figure 4.1). The longitudinal registration produced
deformation fields that contain parameters to warp each time point T1 to the subject-specific T1.
These parameters can then be used to warp the associated BIANCA-produced WMH maps into




Figure 4.1: Example of a single scan subject (a) original T1 image, (b) left-to-right flipped image,
and (c) averaged image.
4.6 Segmentation and normalisation
4.6.1 Cross-sectional
CAT12 (r1278, http://www.neuro.uni-jena.de/cat/), a toolbox of SPM12 (v7219,
http://www.fil.ion.ucl.ac.uk/spm/), running in Matlab 9.3.0.713579 (R2017b), was used to pro-
cess T1-weighted structural images. Briefly, images were bias-corrected, spatially normalised via
DARTEL (using the DARTEL template provided within CAT12, registered to MNI space), mod-
ulated to compensate for the effect of spatial normalisation, and classified into grey matter (GM),
white matter (WM), and cerebrospinal fluid (CSF), all within the same generative model [3]. The
segmentation procedure was extended by accounting for partial volume effects [55], applying adap-
tive maximum a posteriori estimations [40], and using a hidden Markov Random Field model [11].




This step is identical to the cross-sectional segmentation and normalisation, however, the within-
subject template image (i.e., average T1 image) is segmented and normalised. The deformation
fields encompassing the warps from individual time point subjects space to average T1 space, and
average T1 space to standard space (DARTEL) where then combined into a single deformation
field to take individual BIANCA output mask from T1 subject space to standard space in one step.
The deformation composition was done using the SPM12 tool Deformations. This tool combines
the two separate deformation fields into one. In the same step as combining the two deformation
fields, the application of the new deformation field can be applied to the BIANCA output mask
in T1 space to warp the mask in standard space. The resultant image at the end of both the
cross-sectional and longitudinal steams is a normalise (MNI space) WMH map per person per time
point.
4.7 Smoothing BIANCA output mask in standard space
After normalising, each BIANCA output mask was smoothed using an fwhm= 8mm Gaussian
kernel in normalised space. Smoothing was an important step before statistical analysis because
smoothed masks adjust for potential registration errors or inconsistencies in the normalisation
process. Voxel-wise statistical analyses were performed on the smoothed, normalised WMH masks
and the specific statistical tests used in this thesis are outlined in Section (4.10).
4.8 Regional white matter hyperintensity definition
In addition to voxel-wise comparisons, I was interested in investigating the relationship between
regional WMHs and cognition in PD. I extracted lobar WMH volume, as well as periventricular
WMH volume from each participant at each time point from the normalised WMH mask. Brain
lobes (frontal, occipital, temporal, and parietal) were defined using the Montreal Neurological In-
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stitute (MNI) lobe atlases (available with FSL, Figure 4.2b).
The periventricular region was defined by dilating the FSL-provided ventricle mask in standard
space (MNI space) using a spherical kernel with diameter = 7mm [18]. This periventricular region
was then segmented further into anterior and posterior regions by using the frontal lobe junction
to the other three brain lobes as a separation point (Figure 4.2c).
In addition to global volume, the following regional volumes were investigated in this thesis; frontal
lobe, parietal lobe, temporal lobe, occipital lobe, total periventricular region, anterior periventric-
ular region, and posterior periventricular region.
4.9 Analysis: Lesion probability maps
Lesion probability maps (LPMs) are voxel-wise representations of the likelihood of a single voxel
being classed as a WMH. Group-wise LPMs were calculated at baseline in all cognitive categories
(Control, PD-N, PD-MCI, and PDD) by averaging the normalised, smoothed baseline BIANCA
WMH masks. LPMs are a way of visually indicating of the distribution of WMH burden by group.
4.10 Analysis: Statistical methods
I analysed BIANCA output masks using two statistical approaches to determine the potential
importance of WMH burden on cognitive decline in PD. The General Linear Model was used to
assess the difference in the spatial variation of WMHs between different cognitive groups on a voxel-
wise level, as well as any voxel-wise association between global cognitive ability (as a continuous
measure) and WMH volume. When investigating global or lobar WMH volume (i.e., as a single
volume per region), I used Bayesian regression modelling to assess the out-of-sample predictive
power of WMH burden to predict cognitive function. These two statistical analysis methods are






Figure 4.2: (a) Standard MNI152 (Montreal Neurological Institute) T1 1x1x1mm brain image. (b)
Coronal view of brain lobes; frontal (red), occipital (yellow), temporal (green), and parietal (blue).
(c) Sagittal view of brain lobes; frontal (red), occipital (yellow), temporal (green), and parietal
(blue). (d) Coronal view of periventricular region; anterior (red) and posterior (blue).
4.10.1 General linear model
The general linear model (GLM) is an analytical method by which prediction of a dependent vari-
able is carried out with a linear combination of independent variables. The GLM includes statistical
techniques such as Student’s t-test, multiple linear regression, analysis of variance (ANOVA), and
analysis of covariance (ANCOVA) [43]. The GLM includes allowances for predictive variables, and
it functions as a method of evaluating the relationship between constituent variables to explain the
variability in a response variable [20].
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The basic mathematical expression of the GLM is
Y = β0 + β1X1 + ...+ βqXq + ε (4.1)
in which Y is vector response variable, X1, ..., Xq are the explanatory variables, β0, ..., βq the re-
gression coefficients, and ε is an error term to encompass any variation that cannot be described
by the model [20]. In matrix notation, the GLM is written as follows in equation 4.2 where in Y,
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X is a matrix of the available data of the relationship under investigation, β is a vector of unknown
and variable coefficients, and Y and ε are random vectors. The q + 1 rows in the X matrix of
equation 4.2 account for the intercept term of the model, β0. The n× 1 error matrix is the random
error variable and its constituents are assumed to be independently and identically distributed with
a variance of σ2 [43]. Another assumption utilised in the GLM is that the values of the dependent
variable, Y, are a random selection of the population of interest.
4.10.2 GLM design matrix
Group differences (Control/PD-N/PD-MCI/PDD) in spatial WMH volume were assessed with age
and sex as covariates. Results remained unchanged after inclusion of intracranial volume (ICV) as
an additional covariate; results presented in this thesis are without ICV in the model and corrected
for multiple comparisons using threshold-free cluster enhancement (TFCE) (p < 0.05). Figure 4.3
is an example of a design matrix used in this study computing the difference between cognitive
groups WMH burden at baseline. Each different comparison of cognitive group is also known as a
contrast of the GLM.
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Figure 4.3: GLM design matrix created using FSL Make GLM, identifying cognitive status as
the tested effect and includes covariants sex and age at baseline. There are 6 separate pairwise
comparisons tested, with tests specified by c1-6. Each column of the design matrix is binary,
excluding age.
Legend: HC = Healthy Control; PDN = Parkinson’s disease with normal cognition; PDMCI = Parkinson’s disease
with mild cognitive impairment; PDD = Parkinson’s disease dementia.
In addition to the contrasts presented in Figure 4.3, a contrast between healthy controls and all
PD patients at baseline was also tested to evaluate the significant difference between WMH burden
in all controls and all PD patients. The contrast for this investigation is as follows (equation 4.3)
Y = βPD − βHC + 0βsex + 0βage. (4.3)
4.10.3 FSL Randomise
The FSL function Randomise is employed to assess the contrasts set up in the GLM. Randomise
is a statistical permutation method for statistical maps in which the null distribution is unknown
and allows for the investigation of voxel-wise WMH load [58].
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In this study, the inputs for Randomise include a 4D image file of smoothed, normalised BIANCA
output files, the design matrix, and a binary mask excluding non-brain tissues. In this study, the
number of permutations was set to 5000 for the building of the null distribution. All voxel-wise
results were corrected for multiple comparisons using Family Wise Error Rate (TFCE (p < 0.05)).
The output from Randomise include a test statistic image and corrected p-value images for each
contrast tested. Thresholds can then be applied to the p-value images to display only statistically
significant differences in the test variables.
4.10.4 Bayesian regression model
The second statistical analysis method employed in this study was Bayesian multi-level regres-
sion models using the R package Bayesian Regression Models using ‘Stan’ (brms) (https:\\cran.r-
project.org/web/packages/brms/brms.pdf). This method of analysis allows for cross-sectional anal-
ysis as well as determining the predictive power of WMH burden in relation to cognition over time.
In each model, four chains with 4000 iterations each were used to generate posterior samples.
Student-t priors were also included in the models and were set with 5 degrees of freedom, location
= 0 and scale = 10, the default values.
brms analysis allowd for investigation into whether additional knowledge of WMH volume (global
and regional) improves out-of-sample prediction of cognition in an individual when known pre-
dictors of cognition like age and PD diagnosis are already included in the model. brms analysis
considers input variables, or predictors, of a model and calculates each variable’s usefulness for
predicting the outcome variable - cognitive score (global or domain) in this study. Individual pre-
dictors can be compared to determine their predictive power in any given model.
Similar to standard GLM-based regression, assessment of a particular predictor’s usefulness in the
Bayesian fit of the cognition model was evaluated, and considered significant if the upper and lower
95% confidence intervals (CI) for the variable fell exclusively above or below zero(that is, the effect
of a particular predictor was considered significant if the 95% CI did not include 0).
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While most studies stop with a description of the effects of parameters within a particular model,
I took a further step by investigating if including a WMH volume variable provided any additional
information about cognition compared to a simpler model. Model comparison was carried out using
k-Fold cross-validation, a cross-validation technique in which the data is divided into k equal and
random groups and k − 1 groups are used to estimate a classifier (i.e. model prediction value),
followed by the calculation of an error value by testing the calculated classifier on the group ex-
cluded from training [42]. A difference in k-Fold Information Criteria (KFOLDIC) score by at least
twice the standard error of the estimated difference, indicated that there was a significant change
in the out-of-sample prediction errors in any two compared models, where a lower KFOLDIC score
represented an improvement in outcome variable (i.e. cognitive score).
4.10.5 Bayesian regression model comparisons
Question: Can global and/or regional WMH volume predict global cognitive z score in PD? (Cross-
sectional)
Starting with an initial simple BRM of cognition modelled with just an intercept, predictors were
added to the model one-by-one and assessment of the additional predictive power gained by the
model from each variable addition was assessed using the KFOLDIC score. Predictors included
age (in decades), group (control or PD), sex, and intracranial volume (ICV). The model with the
best prediction of cognition using these input predictors was then used as a benchmark compared
to models that also included WMH volume (global and regional) as an additional predictor. All 8
WMH regions specified above were compared to the benchmark model using k-Fold cross-validation.
An example model is as follows: What is the contribution of global WMH load to the prediction
of global cognitive score (cogz) when age, sex, intracranial volume, and group are already known:
Cogz ∼ age+ sex+ ICV + group+WMH(global) vs Cogz ∼ age+ sex+ ICV + group.
Question: Can global and/or regional WMH volume predict specific cognitive domain scores in
PD? (Cross-sectional)
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A similar model comparison was also carried out using cognitive domain scores instead of global
cognitive z score to assess if global or regional WMH volume could improve the predictive model
of specific cognitive domain impairment. This was of particular interest given the dual syndrome
hypothesis, detailed in Section 1.1.3, wherein WMHs in specific regions could have a more signifi-
cant influence on the prediction of different cognitive domain scores. The cognitive scores used in
the models were the mean values for the cognitive domains of interest; executive function, memory,
visuospatial/visuoceptial, and attention. The regions used for this specific investigation included
global, anterior periventricular, and posterior periventricular due to the specific investigation into
the dual syndrome hypothesis in which the periventricular regions are the ones of most potential
influence over cognitive scores in specific domains.
Question: Can baseline WMH volume be used to predict cognitive ability after 6 years? (Longitu-
dinal)
The final models tested in this thesis used a longitudinal subset that included participants with
both baseline and 6-year assessments (Controls = 26, PD = 56). Here, baseline variables were
used to predict global cognitive z score at 6 years from baseline. The initial model used baseline
age, baseline cognitive z score, and group (Control/PD) to predict global cognitive score at 6 years.
I then added baseline global WMH volume to the model. In order to determine whether baseline
global WMH volume increased the out-of-sample prediction of future 6-year cognition, the two




Here, I present both cross-sectional and longitudinal results of the BIANCA-derived, normalised
WMH masks analysis in the context of cognitive decline in PD. Cross-sectional results presented
include:
• The investigation of total WMH volume across cognitive categories,
• Lesion probability maps, which display the distribution of WMHs,
• Baseline comparisons of the relationship between the spatial distribution of WMHs and cog-
nitive decline in PD,
• And Bayesian regression models to specifically investigate the ability of WMHs to predict
cognition both globally and by cognitive domain.
Longitudinal analysis investigated whether baseline WMH volume could improve the prediction of
cognitive score at 6 years after baseline.
All results presented are based on the WMHs identified using BIANCA with optimised parameters,
which I established in Part 1 of this thesis, with each WMH mask normalised according to the
process detailed in Section 4.5.
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5.1 Baseline cognition and white matter hyperintensity results
5.1.1 ANCOVA model
To investigate total WMH volume across differing cognitive groups (Control/PD-N/PD-MCI/PDD),
I used an analysis of covariance (ANCOVA) model, with age and sex as covariates. The overall
ANCOVA model was significant (R2 = 0.22, F (5, 222) = 14, and p < 0.001). This was driven by
an association between WMH volume and age. Tukey HDS post hoc tests were used for pairwise
comparisons across the cognitive categories (included in Appendix A.1) in which there were no
significant pairwise results across any of the different cognitive categories.
Baseline WMH volume across the 4 cognitive categories is displayed in Figure 5.1. The median
volume values for the Control and PD-N group was comparable at 11.9ml and 11.7ml, respectively.
The median values then increase for PD-MCI and again for PDD to 15.3ml and 17.6ml, respectively,
but as documented above, these were not significantly different.
Figure 5.1: Baseline boxplot of white matter hyperintensity volume (WMH + 1) across categories;
Control, PD-N, PD-MCI, and PDD. Each data point represents a unique subject with baseline
MRI and neuropsychiatric assessment.
Legend: PDN = Parkinson’s disease with normal cognition; PD-MCI = Parkinson’s disease with mild cognitive
impairment; PDD = Parkinson’s disease dementia; WMH = White matter hyperintensity.
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5.1.2 Lesion probability maps
Baseline LPMs were calculated for all cognitive categories (Control, PD-N, PD-MCI, and PDD),
and visually show the extent of the likelihood of a region being hyperintense in the group. Even
though global WMH volume did not differ statistically significantly by cognitive category, visually
the LPMs become more extensive in PD as the cognitive status worsens (Figure 5.2) with PD-MCI
and PDD LPMs growing slightly in size and probability as shown by the increasing yellow regions
around the ventricles. The colour scale for these LPMs are all manually set corresponding to prob-
ability 0.05-0.5(5-50%) to emphasise the variability of the maps between the 4 categories as the
maximum probability across all maps was 0.47(47%) in the PDD LPM (Figure 5.2d).
5.1.3 Randomise statistical comparison of spatial distribution across groups
While LPMs provide a purely visual representation of the distribution WMHs per cognitive cat-
egory, I also statistically tested whether WMH distribution varied across these categories using a
spatial GLM implemented in FSL. As for the global WMH ANCOVA model, here I investigated
the relationship between spatial WMH volume and cognitive status, with age and sex as covari-
ates. There were statistically significant areas WMH volumes in PD-MCI and in PDD relative to
Controls (TFCE-corrected p < 0.05) as presented in the Figure 5.3. The significant regions appear
predominantly on the right side of the brain in PD-MCI vs Control (Figure 5.3a), and the limited
significant regions appear on the left side in PDD vs Control (Figure 5.3b). There were no other
significant pairwise differences, i.e. there were no significant differences between PDN and Control,
or within PDN, PD-MCI, and PDD. The lack of resounding pairwise comparison results from the
Randomise comparison reflected the global ANCOVA results in Section 5.1.1.
I also restricted the analysis to PD only, in order to add disease duration, motor impairment (UP-
DRS part III), and LED to the model. There were no significant regions of difference between
PDN, PD-MCI, and PDD (TFCE-corrected p < 0.05). This finding is again consistent with the
Tukey statistical results that reported no significant results in the distribution of baseline WMH




Figure 5.2: Lesion probability maps (LPMs) at baseline across the 4 cognitive groups. All data
smoothed using a fwhm= 8 Gaussian kernel. Probability colour scale from 0.05 to 0.5. (a) Baseline
Control LPM (b) Baseline PD-N LPM (c) Baseline PD-MCI LPM (d) Baseline PDD LPM.
Legend: PDN = Parkinson’s disease with normal cognition; PD-MCI = Parkinson’s disease with mild cognitive
impairment; PDD = Parkinson’s disease dementia.
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(a) (b)
Figure 5.3: Red-yellow indicated significantly higher WMH volume at baseline in (a) PD-MCI vs
Control and (b) PDD vs Control, accounting for age and sex. Significant results displayed for
p < 0.05.
Legend: PD-MCI = Parkinson’s disease with mild cognitive impairment; PDD = Parkinson’s disease dementia.
5.2 Baseline white matter hyperintensity volume with age
5.2.1 Global and regional white matter hyperintensity volume
Using a scatter plot at baseline, the relationship between increasing WMH volume and advancing
age was investigated. Figure 5.4 shows WMH volume increased in older patients on both a global
(Figure 5.4a) and regional level (Figure 5.4b). Note that there is a spread of cognitive status in
which PD-N, PD-MCI, and PDD subjects have no distinctive separation of WMH volumes.
I also calculated correlation coefficients to quantify the relationship between global WMH volume
and age. Table 5.1 presents the Pearson correlation coefficient values and accompanying p-values
for each region presented in the age vs WMH volume scatter plot (Figure 5.4b), as well as additional
periventricular regions. Correlation coefficients for total baseline data, both across the whole sample
as well as within Controls and PD were statistically significant of p < 0.01. Limited statistically





Figure 5.4: Baseline WMH volume in control and PD (a) globally, and (b) regionally in lobes;
Frontal, Occipital, Parietal, Temporal. The colour of points corresponds to the cognitive category
of the subject at baseline as indicated by the key; Light blue = Control, Dark blue = Control-MCI,
Green = PD-N, Yellow = PD-MCI, Red = PDD.
Legend: PD = Parkinson’s disease; PDN = Parkinson’s disease with normal cognition; PD-MCI = Parkinson’s disease
with mild cognitive impairment; PDD = Parkinson’s disease dementia; WMH = White matter hyperintensity.
5.2.2 Randomise statistical comparison between age and white matter hyper-
intensity volume
Spatial correlation of WMH volume at baseline was investigated using Randomise to produce
correlation maps with baseline age. Significant and extensive correlation was presented in the
periventricular regions of the brain (Figure 5.5).
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Region PD and control correlation coefficient Control correlation coefficient PD correlation coefficient
Global 0.46(< 0.001) 0.37(0.010) 0.49(< 0.001)
Frontal 0.50(< 0.001) 0.41(0.003) 0.52(< 0.001)
Occipital 0.28(< 0.001) 0.07(0.626) 0.33(< 0.001)
Parietal 0.40(< 0.001) 0.31(0.030) 0.43(< 0.001)
Temporal 0.25(< 0.001) 0.19(0.182) 0.28(< 0.001)
Periventricular 0.49(< 0.001) 0.35(0.125) 0.53(< 0.001)
Anterior periventricular 0.56(< 0.001) 0.45(0.001) 0.51(< 0.001)
Posterior periventricular 0.39(< 0.001) 0.25(0.080) 0.42(< 0.001)
Table 5.1: Pearson correlation coefficients between regional WMH volume and age at baseline,
with correlation coefficients calculated for all subjects (PD and control) and groups PD and control
individually. Data presented as correlation coefficient(p-value). Statistically significant results are
presented in bold.
Legend: WMH = white matter hyperintensity; PD = Parkinson’s disease.
Figure 5.5: Baseline correlation map for white matter hyperintensity volume and age calculated at
baseline. Significant results displayed for TFCE-corrected p < 0.05.
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5.3 Cross-sectional Bayesian approach: Prediction of global cog-
nitive ability
Cross-sectional analysis using the full cohort (i.e. all scans from all time-points were included and
multiple scans per subject were modelled hierarchically) was carried out to investigate if WMH
volume could be used as a predictor of current cognitive status, with and without additional data.
An investigation into regional WMH effects on specific cognitive domains as well as global cognition
was also carried out.
5.3.1 Global cognitive z score
Predictors not including WMH volume were compared to the initial model first (i.e. cognitive z
modelled using only an intercept). Using KFOLDIC, it was determined that the inclusion of group
(Control or PD) and age in conjunction improved the predictive power of the model significantly.
The inclusion of sex and intracranial volume (ICV) did not improve the predictive power of the
model further using the same k-Fold cross-validation, so they were excluded for all subsequent
model comparisons.
From this point, models including group and age were then augmented to include WMH volume
for all the individual regional WMH volumes under investigation, i.e. global, frontal, temporal,
occipital, parietal, PV, anterior PV, and posterior PV regions; a new model was fitted for each
region. None of the WMH regions investigated improved prediction of global cognitive z score when
age and group were already included in the model (Table 5.2). All model comparisons are presented
in Appendix A.2.
5.3.2 Cognitive domain scores
An investigation was also carried out to test the regional influence of WMH volume on specific
cognitive domain scores. Attention, executive function, visuospatial, and memory and learning
domains were tested using domain scores across all participants. The only regions of WMHs used
for predicting cognitive domain scores were global, PV, anterior PV, and posterior PV since this




































































































































































































































































































































































































































































































































































































































































































Cognitive domain Model 1 Model 2 KFOLDIC SE
Attention Initial model Age + group model 84.54 21.06
Attention age + group model age + group + global WMH model -22.90 11.5
Attention Age + group model Age + group + anterior PV WMH model 40.01 14.73
Attention Age + group model Age + group + posterior PV WMH model 11.49 15.75
Visuospatial Initial model Age + group model 41.16 15.41
Visuospatial Age + group model Age + group + global WMH model 3.42 9.91
Visuospatial Age + group model Age + group + anterior PV WMH model -11.98 9.39
Visuospatial Age + group model Age + group + posterior PV WMH model 0.84 8.11
Memory initial model Age + group model 43.26 13.97
Memory Age + group model Age + group + global WMH model 8.04 10.58
Memory Age + group model Age + group + anterior PV WMH model 14.74 11.02
Memory Age + group model Age + group + posterior PV WMH model 2.93 12.17
Executive function Initial model Age + group model 56.80 20.25
Executive function Age + group model Age + group + global WMH model 17.50 14.25
Executive function Age + group model Age + group + anterior PV WMH model 41.27 17.35
Executive function Age + group model Age + group + global posterior PV WMH model -14.79 13.43
Table 5.3: Summary of k-Fold cross-validation information criteria values and standard error for
models predicting mean cognitive domain score. Predictors included in the model comparison are
specified in each model. A positive KFOLDIC indicates an improvement between model 1 and
model 2, with a KFOLDIC being considered statistically significant if it is at least double the value
of the standard error. Bold text highlights models with significant improvement from models 1 to
model 2.
Legend: KFOLDIC = k-Fold information criteria; SE = standard error; PV = periventricular; WMH = white matter
hyperintensity.
The domain scores KFOLDIC values were consistent to the global cognitive z score KFOLDIC value
when comparing the initial model (intercept only) and the age + group model, with statistically
significant improvements in KFOLDIC value in all tested cognitive domains (Table 5.3). There
were also significant improvements reported in the models that included anterior PVWMH volume
in the attention and executive function domain models. The comprehensive model comparison
tables can be found in Appendix A.3.
5.4 Longitudinal white matter hyperintensity analysis
Longitudinal analysis was carried out in two ways; firstly using all available WMH volume and age
data to assess longitudinally, and secondly using baseline and 6-year follow-up data to assess the
power of baseline WMH volume in the prediction of future cognition.
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Figure 5.6: Global white matter hyperintensity volume at all collected time points. Each data point
represents a MRI and cognitive assessment, and a line connecting two or more points joins follow-
ups of an individual at multiple time points. Colour of each data point represents the cognitive
status of the subject at the time of the assessment, and the colour of the line connecting two points
corresponds to cognitive status at the first point.
Legend: PD = Parkinson’s disase; PDN = Parkinson’s disease with normal cognition; PD-MCI = Parkinson’s disease
with mild cognitive impairment; PDD = Parkinson’s disease dementia.
5.4.1 Global white matter hyperintensity volume over time
Global WMH volume was correlated with advancing age when all data for all time points were
considered (Figure 5.6), with Pearson correlation values for Controls ρ = 0.44, p < 0.001, PD
ρ = 0.41, p < 0.001. It should be noted that high WMH volumes are also observed for PD patients
with all cognitive statues (i.e. PD-N, PD-MCI, and PDD) as well as Controls, and the ranges of
WMH volume are comparable across all cognitive categories .
5.4.2 Cognitive score 6 years from baseline
Figure 5.7 shows a plot of WMH volume vs change in cognitive z score at 6 years from baseline.
The Pearson’s correlation coefficient was ρ = −0.18, p = 0.001. There is also an emerging pattern in
the plot which suggests that better cognitive ability at baseline is related to better future cognition.
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Figure 5.7: Baseline white matter hyperintensity volume vs cognitive z score change over 6 years.
Cognitive category as indicated by data point colour is the category at 6 years from baseline.
ρ = −0.18, p = 0.001.
5.4.3 Longitudinal model comparisons
Here I tested the predictive power of baseline parameters for cognition at a specified follow-up time
point, 6 years from baseline (yfbl). This 6-year follow-up time restriction reduced the sample size
to n = 81 for this particular analysis. Modelling cognition at 6 yfbl using baseline age, group
(Control and PD), and baseline global WMH volume showed that global WMH volume improved
the predictive model fit. The 95% confidence interval did not cross zero and thus was considered
statistically significant. The effect size of the predictors of the 6 yfbl model are presented in Table
5.4a. The sign of the estimate value indicates the direction of change in cognition after 6 years.
The positive estimate value for baseline cognitive z score indicates that a lower baseline cognitive
z score is predictive of a lower 6 yfbl cognitive z score. The negative estimate values for baseline
age and baseline WMH volume indicate increased age or WMH burden at baseline is indicative of
a lower 6 yfbl cognitive z score. The positive estimate for group indicates that PD diagnosis at
baseline is predictive of lower 6 yfbl cognitive z score.
Table 5.4b presents the model comparison of the 6 yfbl models, one without baseline WMH volume.
The KFOLDIC value suggests there was no predictive value added to the 6-year cognition model
when baseline WMH volume was included.
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Predictors Estimate Estimate error Lower 95 confidence interval% Upper 95 confidence interval%
Intercept 0.47 0.18 0.12 0.85
Cognitive z score 1.14 0.06 1.03 1.25
Age (decade) -0.11 0.04 -0.19 -0.03
Group (Control or PD) -0.43 0.07 -0.58 -0.29
WMH volume -0.13 0.07 -0.26 -0.00
(a) Summary of model results prediction models of cognitive z score at 6 years from baseline including
WMH volume. All predictors are baseline values. All predictors had significant influence on future cognitive
prediction by non zero crossing 95% confidence interval.
Model KFOLDIC SE
Baseline cognition, age, and group 489.54 29.77
Baseline cognition, age, group, and WMH 487.90 31.43
Model without WMH - Model with WMH 1.64 5.10
(b) KFOLDIC comparison between 6-year cognition prediction models. Significance difference in models
shown a KFOLDIC value of two times the SE value.
Table 5.4: 6 years from baseline cognitive prediction model predictor estimates (a) and KFOLDIC
values (b).




6.1 Review of study results
The work done and presented in this thesis has been separated into 3 main investigations and a
summary of the results are provided here.
Firstly, I determined that in our cohort, BIANCA produced WMH masks that most closely matched
the gold-standard manual masks. BIANCA was further optimised by using bias-corrected input
images and exclusion masks on the resultant BIANCA output WMH masks to reduce false positive
WMH detection. I then applied BIANCA to the entire cohort to create WMH masks in all partic-
ipants at all time points.
At cross-section, I showed a statistically significant relationship between increased WMH volume
and advancing age. However, the analysis did not produce any statistically significant differences in
WMH volume between cognitive categories in PD or compared to Controls. There was also limited
significant results reported from the Bayesian model comparisons run at baseline for global and
regional WMH volume in global z score and mean cognitive domain scores, with anterior PVWMH
the only region that was found to improve the prediction of executive function and attention do-
main scores.
The longitudinal analysis utilised data from baseline and at 6 years follow-up. I found that al-
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though baseline WMH volume was a significant predictor for future cognitive ability, it provided
little additional information once age, group (Control or PD), and baseline cognitive ability were
known.
In the following sections I will elaborate on the findings presented in Chapter 5 and summarised in
here.
6.2 Baseline cognition and white matter hyperintensity volume
6.2.1 Global white matter hyperintensity volume
Baseline ANCOVA results suggested little evidence of an association between WMH burden and
cognitive status. It is visually apparent in the boxplot (Figure 5.1) that high WMH volume is
seen across Controls and the 3 constituent PD cognitive categories. The subtle median volume
increase across the cognitive categories was very small, and the ranges of WMH volumes in all
four categories were large, indicating substantial overlap in WMH volumes across all participants.
Hence, the boxplot and associated ANCOVA model suggested that WMH volume did not differ
across cognitive groups in PD. This in turn also indicated that WMH volume alone did not give
a reliable prediction of the cognitive category on an individual level due to the overlap of WMH
volumes presented across all categories.
6.2.2 Baseline lesion probability maps
The baseline LPMs make it visually apparent that the periventricular region is where WMHs are
consistently likely to be located (Figure 5.2). With a number of cross-sectional studies reporting
an association between PVWMH and worsening cognition in older adults [6], these LPMs support
this finding, although not in a quantifiable, significant way. Visually, the LPMs did no appear to
support the hypothesis that cognition worsens with increasing WMH burden.
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6.2.3 Baseline spatial white matter hyperintensity distribution
Both PD-MCI and PDD exhibited significantly increased voxel-wise WMH volume relative to Con-
trols, however, there were no significant differences in voxel-wise WMH volume across PD cognitive
categories.
The PD-MCI vs Control comparison (Figure 5.3a) was more extensive than the PDD vs Controls
comparison, however, there were no significant differences between PD-MCI and PDD when directly
compared. The potential reason we may see the larger spatial extent of WMH increases in the PD-
MCI vs Control comparison is the larger number of PD-MCI scans compared to PDD scans, and
hence greater statistical power to identify a potentially small effect (71 PD-MCI vs 27 PDD). With
this difference in category size in mind, it can be concluded that there may exist a slight increase
in WMH volume anterior and posterior periventricular regions in PD-MCI and PDD compared to
Controls.
6.3 Baseline age and white matter hyperintensity volume
I found evidence of the well-reported association between increasing age and increasing global WMH
volume (Figure 5.4). This observation is in agreement with reviewed literature [24, 38, 53], and
is observable both globally and regionally (Figure 5.5). Observation of this robust relationship
acts as an internal check to processing methods used in this thesis. That is, while my primary
question pertained to the relationship between WMH volume and cognition in PD, demonstrating
the relationship between WMH volume and age in this cohort suggests that both imaging processing
and analysis were not flawed or reporting misleading results. The analysis of the Pearson correlation
coefficients in Controls and PD, both separately and as a single group supported the emerging
association between age and WMH volume with statistically significant correlation coefficients
reported for all brain regions in exclusively PDs and in Controls and PDs (Table 5.1). All these
results collectively indicate that increased WMH volume, particularly periventricular, is correlated
with advancing age in our cohort.
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6.4 Cross-sectional Bayesian models
Cross-sectional model comparisons indicated that we once again see an effect of increasing age and
increasing global WMH burden. There is, however, no evidence of increased WMH burden associ-
ated with PD or cognitive decline within PD, and a limited association between WMH burden and
domain-specific cognitive ability (Table 5.2).
Interestingly, anterior PVWMH significantly increased out-of-sample prediction of attention and ex-
ecutive function domains (Table 5.3). Anterior dysfunction is implicated in worsening performance
in both attentional processes and executive functions according to the dual syndrome hypothesis
[27]. The results from this cross-validation investigation support this relationship with anterior
PVWMH volume, significantly improving the appropriate models with the inclusion of anterior
PVWMH volume. There is, however, a lack of support for the accompanying posterior dysfunc-
tion of the dual syndrome hypothesis which implicates worsening memory and visuospatial domain
scores. The inconsistencies in the findings for the anterior and posterior PVWMH volumes and
the influence of the volumes on the associated cognitive domains in our sample fails to provide
convincing support or denial of the dual syndrome hypothesis.
6.5 Longitudinal analysis
6.5.1 Longitudinal age vs white matter hyperintensity volume
While WMH volume was shown to be related to increasing age, shown in this cohort and others,
there were some subjects in this cohort that displayed decreasing WMH in time (Figure 5.6). While
WMHs can become less intense over time in some situations (for example, in multiple sclerosis ac-
tive lesions can change appearance on a T2 FLAIR image), this is relatively unlikely in an older,
PD cohort. This suggested decrease in WMH volume in some subjects over time may represent
inconsistencies in the WMH identification of BIANCA, even though BIANCA produced the best
maps relative to the manually segmented gold-standard.
These inconsistencies in BIANCA could be because the algorithm doesn’t include a longitudinal
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pipeline, in which it would take into account the multiple scans from the same individual, which
could improve the issue of apparently decreasing WMH burden over time. This considered, there
is still an upward trend overall of WMH volume with increasing age as expected.
6.5.2 6-year follow-up cognition
The 6-year follow-up cognition investigation resulted in a weak correlation between increased base-
line WMH volume and the amount of cognitive change experienced in the 6 years from baseline
(ρ = −0.18, p = 0.001, Figure 5.7). This result suggests that baseline WMH volume could be
used to predict future cognition, but volume could not be used alone to predict cognitive change.
Perhaps additional variables such as age or baseline cognition could be used in conjunction with
WMH volume to improve prediction, but at a subject level, baseline WMH volume could not be
used to predict future cognition in PD or otherwise.
It should be noted that there are few PDDs included in this longitudinal analysis. This could be due
to the loss of PDD participants across the 6-year follow-up period to discontinued participation in
the study, or individual inability to complete MRI scan or cognitive testing. This, in turn, restricts
the sample of PDs in this investigation to predominantly PD-N and PD-MCI participants. Having
a data set more representative of all cognitive categories in PD could alter the predictive power of
the baseline values employed by the model. However, the 6-year follow-up period restricts the data
since individuals who digress from PD-MCI or even PD-N to PDD over the follow-up period may
have difficulty completing the rigorous testing required at the follow-up time point.
6.5.3 6-year follow-up cognitive prediction models
6-year prediction models were tested to evaluate the ability of WMH volume to predict future
global cognitive score. Using known baseline values to model known future cognitive scores at a
consistent follow-up time point allowed me to assess if the inclusion of additional predictors in the
models improved the prediction of future global cognition. At the group level, I showed a significant
relationship between baseline global cognitive ability, age, whether a person had PD, and global
WMH volume (Table 5.4a).
71
However, when investigating the predictive power of each variable on the individual level (assessed
using KFOLDIC), baseline WMH volume did not add any additional information about 6-year
cognitive ability (Table 5.4b). Baseline values of cognitive z score, age, and group did, however,
provide independent and significant predictive information about future cognition. That is, all
three variables provided additional, useful information about future cognitive ability. The appar-
ent contradiction between the group-level results (WMH volume had a significant association with
6-year cognitive ability) and the individual-level results (once baseline cognitive z, age, and group
status were known, WMH contributed no additional information) can be explained by the partial
collinearity of the input variables. Baseline cognitive z, age, and group status contain similar in-
formation to global WMH volume; therefore, while a relationship exists on the group level, WMH
volume fails to improve out-of-sample prediction of future cognition on the individual level. Not
surprisingly, baseline cognitive z score provides the greatest predictive power for 6-year cognitive z
score. That is, current cognition is the best predictor of future cognition (Table 5.4a).
6.6 Interpretation of results
The research carried out in this thesis has clinical implications as the relationship between cogni-
tion and WMHs in PD is divided in current literature, as discussed in Section 1.2.3. The results
presented in this thesis indicate that WMH volume does not hold the significant predictive power
suggested by some previous reports in this large, longitudinal cohort [16, 54]. Considering the
results presented above, WMHs do not add any more information or power to cognition prediction
models once other factors that have well established and supported correlations to cognition are
considered, like age and PD diagnosis.
One possible reason WMH volume fails to provide convincing predictive power to cognition models
is that the effects predicted by WMH volume are absorbed by confounding predictors used. The
well established and supported correlation between cognition and age is an example of this, in
which increasing age is correlated with decreasing cognition, specifically in PD patients [59]. In
addition to this, I demonstrated there is a correlation between increasing WMH volume and age in
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Section 5.4.1. With both increased WMH volume and worsening cognition clearly correlated with
advancing age, there is the potential that the full predictive power of WMH volume on cognition is
absorbed by the predictive power of age. The interconnectedness of these variables with each other
could cause a ‘watering down’ of the prediction effects of WMH on cognition in PD. Age remains
in the cognition prediction models because of the strength of predictive power it provides to the
model and removing it to allow all the predictive power to go to WMH volume results in worse
model fitting.
Clinically, the work done in this thesis indicates that WMHs should not be considered a clinically
useful biomarker for cognitive decline in PD or even for the presence of PD. There are weak
indications that specific WMHs located in anterior PV regions are more closely associated with
attention and executive function, but the inconsistencies that arise from the posterior PV region
adding no additional predictive power for visuospatial or memory domains remains unresolved.
6.7 Study strengths and limitations
The findings of this thesis generally align with much of the literature reviewed that reports no
significant relationship between WMH volume and cognitive decline in PD. A major strength of
this study is the large longitudinal cohort of PD patients and matched healthy controls used for
comparison, providing the opportunity for both cross-sectional and longitudinal analysis of WMH
volumes and cognition. Our cross-sectional cohort comprised 258 participants, a large cohort com-
pared to most previous studies, with other PD specific cross-sectional cohorts of 111 participants
(PD-N = 39, PD-MCI = 46, PDD = 26) [16], and 90 participants (PD-N = 65, PD-MCI = 25) [31]
being reviewed.
Rigorous cognitive testing is a major strength of this study with all cognitive domains assessed and
mean domain scores for each calculated that could be used for the regional effect of WMHs. Having
a thorough cognitive battery as part of our study as well as consistent follow-up of participants is
an added strength to this work.
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In addition to having an extensive cross-sectional cohort, 81 of the 258 individuals in our cohort
contributed to the longitudinal component of this data (Control = 26, PD-N = 26, PD-MCI = 27,
PDD = 2). Having longitudinal cognitive and imaging data has added another layer to this study
in which future cognition in PD could be investigated. Reviewed literature of a similar nature
included a study by Dadar et al. (2018) that used a cohort of PD patients and healthy controls to
test the significance of WMH volume in terms of cognition (Control = 174, PD = 365)[12]. We were
unable to reproduce the results of the study by Dadar et al., which indicate that spatial information
of WMH significantly improved prediction of cognition, and a higher WMH volume in PD patients
is indicatived of faster cognitive decline compared to low WMH volume PD patients and high
WMH volume matched controls. The discrepancies in these findings could be due to the different
WMH identification methods and cognitive tests used in the respective studies, or the differences
in cohorts, particularly the large number of Controls and PDs included in the study by Dadar
and colleagues. A larger cohort could have made the correlation tests more sensitive to increases in
WMH volume with worsening cognition, following the effect observed and discussed in Section 6.2.3.
The different statistical analysis method between this study and others should be considered as I
extended the analysis beyond the group-level analysis where many other studies do not. The sta-
tistical test presented in Section 5.4.3 investigating 6-year follow-up cognition prediction reported
similar findings at the group-level (Table 5.4a), when the statistical tests were investigated further
to an individual level, the significance of the relationship between WMHs and cognition was not
sustained (Table 5.4b). The inconsistency between group-level and individual-level statistical tests
are due mainly to correlated variables used in the models, discussed in Section 6.5.3.
One limiting factor of this study is the potential overestimation of WMH volume by BIANCA in our
cohort. Although a quarter of the BIANCA training subjects had low WMH burden specifically to
address this issue, other low WMH burden subjects not included in the training data appeared to
have false positives in the BIANCA output masks after post-processing masking and small cluster
removal. As stated in the sampled literature, BIANCA has been reported to overestimated ‘dirty
WM’, WM that bordered on hyperintense but have poorly defined margins [30]. The results from
our study indicate higher mean WMH values compared to others in literature [12], with a mean
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WMH volume value of 17 ml (range 4.4 - 73.6 ml). The larger mean value in comparison to other
studies again emphasises the impact of overestimation of the low burden subjects seen in this study.
This overestimation was not completely eliminated from our cohort and is manifest in the smallest
WMH volumes of 3.8cm3. Visual inspection of the subjects with the lowest WMH volume as cal-
culated by BIANCA makes it clear that some dirty white matter has been picked up in low burden
subjects, and are regions that could have been eliminated in manual WMH identification. However,
the higher WMH volume subjects have consistently accurate WMH detection, and this overestima-
tion for very low burden subjects is a trade-off considered in achieving the best estimation of WMH
masks for the cohort as a whole. In addition, the accuracy of BIANCA across the high and low
burden subjects in this cohort was found to be more consistent than the other algorithms tested,
so the use of BIANCA for WMH identification remains justified.
Another potential limiting factor of this work could be present in the coregistration step. When
coregistering the T2 FLAIR to the T1, I coregistered and resliced the WMH mask to T1 space, which
then needed to be thresholded to return to a binary image. I later learned that this step could have
been avoided by using the ‘Coregister: Estimate’ option in SPM. ‘Coregister: Estimate’ calculates
the coregistration matrix between two images, and then adjusts only the header information of
this image, without reslicing the image (which avoids interpolation inherent in reslicing). In the
future, I would recommend avoiding unnecessary instances of reslicing data. However, all images
in the cohort were processed in a consistent pipeline. Therefore, any noise generated by the extra
reslicing step should be (1) minimal, and (2) consistent across all participants, which reduces the
chance of affecting any of the statistical comparisons I investigated.
6.8 Future work
There is potential for future work following on from the findings presented in this thesis. One
avenue of investigation could be into the significant improvement in cognitive score prediction in
executive function and attention with the inclusion of anterior periventricular WMHs on the mod-
els in addition to age and group (PD and Control) (Section 5.3.2). Further investigation to this
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finding could help to illuminate the implications this finding has on the dual syndrome hypothesis,
and tend to the missing link of the posterior periventricular WMH relationship to cognitive domain
scores we would expect to see if WMHs were a biomarker of the dual syndrome hypothesis.
There is also potential to further refine the WMH identification process. While BIANCA was
clearly the best WMH identification algorithm in the training data set (initial set n=20 and ex-
tended set n=40), the issues of overestimation, as discussed above, could be improved. This would
further strengthen the findings of this work. There is also potential for combining WMHs with
other comorbidities or biomarkers to achieve a stronger relationship between WMH and cognitive
decline in PD. This could include, but is not limited to, biomarkers present in other brain imaging
modalities, neuropsychological tests or scores, or haematological biomarkers.
6.9 Concluding comments
The work carried out in this thesis consisted primarily of two main investigations; the identification
of the optimal WMH identification algorithm to use on our large longitudinal cohort of PD patients,
and to then use that algorithm’s results to investigate the correlation between WMH volume and
cognitive impairment in PD.
Of the four WMH identification algorithms investigated, BIANCA was determined to be the best
for our cohort with the highest performance measures across the board. BIANCA was trained
using 40 mixed WMH burden subjects, and bias-corrected input images to achieve the most accu-
rate WMH identification. The resulting outputs produced by BIANCA were used to identify the
correlation between WMH volume and cognitive impairment and worsening among PD patients,
and compared to healthy controls.
Our baseline results supported the finding that WMH volume increases with age. The LPMs and
the associated statistical tests, however, failed to convincingly support increasing WMH volume
correlation with worsening cognition in PD in comparison to Controls and within the PD cohort.
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Statistical maps calculated comparing PD-MCI and PDD patients with healthy controls produced
restricted significant areas of increased WMH volume, notably more drastically for PD-MCI than
PDD, possibly due to the larger number of patients in the cognitive group compared to PDDs al-
lowing for more subtle effects to be detected. This finding loosely supports the claim that worsening
cognition in PD is correlated to increased WMH volume when compared to healthy controls, but
the same finding was not reported within PD. There is also no evidence from this investigation that
there is any emerging spatial dependence of cognition on WMHs. Overall, these results provided
weak support for increasing WMH volume and worsening cognition.
The cross-sectional predictive investigation of this study reported that specific regions of WMHs do
not improve the prediction of global cognitive z score. When cognition is broken down further into
cognitive domains, anterior PV regions emerge as improving variables for attention and executive
function domain score prediction when age and group is already considered. These results align
with one of the two syndromes in the dual syndrome hypothesis such that attention and executive
function are suggested to be impacted more significantly by frontal cortical dysfunction, with ante-
rior PVWMHs contributing to this dysfunction. However, lack of support for the other syndrome
involving posterior cortical dysfunction effects on memory and visuospatial domain dysfunction
renders this in need of further investigation.
For the longitudinal investigation in this study, baseline WMHs were used to test if they could
be used to predict the future cognition of an individual. While group-level analysis reported a
statistically significant estimate for WMH volume prediction of future cognition, subject-level in-
vestigation indicated no improvement in future cognitive function prediction. This suggests again
that WMH volume does not add any predictive power of cognition when predictors such as age or
PD diagnosis are already accounted for.
While WMH burden showed promise as a biomarker of cognitive decline in PD, this work has shown
that they provide only a weak indication of future cognition, if at all. While the importance of
WMH in ageing has been shown, WMHs do not appear the driving pathology of cognitive decline
in PD. Other avenues of WMH biomarker detection will need to be investigated - potentially using
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MRI/PET techniques. Perhaps WMHs in combination with other modalities will yield a better
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Table A.1: Tukey Post Hoc Test
Linear Hypotheses Estimate Standard Error t value Pr (> |t|)
PDN - Control == 0 0.075 0.088 0.854 0.825
PD-MCI - Control == 0 0.171 0.089 1.924 0.217
PDD - Control == 0 0.261 0.117 2.232 0.115
PD-MCI - PDN == 0 0.096 0.082 1.163 0.646
PDD - PDN == 0 0.186 0.115 1.623 0.363
PDD - PD-MCI == 0 0.090 0.108 0.833 0.836
PD-N = Parkinson’s disease normal cognition; PD-MCI = Parkinson’s disease mild cognitive impairment; PDD =
Parkinson’s disease dementia; MoCA = Montreal Cognitive Assessment.
87
Table A.2: Cognitive z score models











cogz.int.data - cogz.group.age.data 104.9 22.5
cogz.int.data - cogz.group.age.data 99.49 21.9
cogz.int.data - cogz.group.age.frontal.data 100.86 20.57
cogz.int.data - cogz.group.age.temporal.data 79.84 17.44
cogz.int.data - cogz.group.age.occipital.data 100.59 20.49
cogz.int.data - cogz.age.group.parietal.data 79.43 20.86
cogz.int.data - cogz.group.age.PV.data 98.34 21.31
cogz.int.data - cogz.group.age.antPV.data 99.32 22.74
cogz.int.data - cogz.group.age.postPV.data 85.99 19.22
cogz.group.age.data - cogz.group.age.data -5.4 14.73
cogz.group.age.data - cogz.group.age.frontal.data -4.04 12.55
cogz.group.age.data - cogz.group.age.temporal.data -25.06 13.71
cogz.group.age.data - cogz.group.age.occipital.data -4.31 12.53
cogz.group.age.data - cogz.age.group.parietal.data -25.47 14.18
cogz.group.age.data - cogz.group.age.PV.data -6.56 12.41
cogz.group.age.data - cogz.group.age.antPV.data -5.58 14.29
cogz.group.age.data - cogz.group.age.postPV.data -18.9 10.86
cogz.group.age.data - cogz.group.age.frontal.data 1.36 12.35
cogz.group.age.data - cogz.group.age.temporal.data -19.66 12.28
cogz.group.age.data - cogz.group.age.occipital.data 1.1 12.52
cogz.group.age.data - cogz.age.group.parietal.data -20.07 14.84
cogz.group.age.data - cogz.group.age.PV.data -1.15 12.33
cogz.group.age.data - cogz.group.age.antPV.data -0.17 13.91
cogz.group.age.data - cogz.group.age.postPV.data -13.5 11.63
cogz.group.age.frontal.data - cogz.group.age.temporal.data -21.02 11.33
cogz.group.age.frontal.data - cogz.group.age.occipital.data -0.27 10.99
cogz.group.age.frontal.data - cogz.age.group.parietal.data -21.43 12.78
cogz.group.age.frontal.data - cogz.group.age.PV.data -2.52 10.03
cogz.group.age.frontal.data - cogz.group.age.antPV.data -1.54 10.62
cogz.group.age.frontal.data - cogz.group.age.postPV.data -14.87 9.76
cogz.group.age.temporal.data - cogz.group.age.occipital.data 20.75 10.73
cogz.group.age.temporal.data - cogz.age.group.parietal.data -0.41 11.58
cogz.group.age.temporal.data - cogz.group.age.PV.data 18.5 11.69
cogz.group.age.temporal.data - cogz.group.age.antPV.data 19.48 13.5
cogz.group.age.temporal.data - cogz.group.age.postPV.data 6.16 9.79
cogz.group.age.occipital.data - cogz.age.group.parietal.data -21.16 11.49
cogz.group.age.occipital.data - cogz.group.age.PV.data -2.25 10.84
cogz.group.age.occipital.data - cogz.group.age.antPV.data -1.27 12.85
cogz.group.age.occipital.data - cogz.group.age.postPV.data -14.6 9.05
cogz.age.group.parietal.data - cogz.group.age.PV.data 18.91 12.52
cogz.age.group.parietal.data - cogz.group.age.antPV.data 19.89 13.43
cogz.age.group.parietal.data - cogz.group.age.postPV.data 6.56 11.91
cogz.group.age.PV.data - cogz.group.age.antPV.data 0.98 10.29
cogz.group.age.PV.data - cogz.group.age.postPV.data -12.35 9.57
cogz.group.age.antPV.data - cogz.group.age.postPV.data -13.33 12.03
PD-N = Parkinson’s disease normal cognition; PD-MCI = Parkinson’s disease mild cognitive impairment; PDD =
Parkinson’s disease dementia; MoCA = Montreal Cognitive Assessment.88
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V
.d
a
ta
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9
8
9
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u
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ou
p
.d
a
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-
v
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u
o
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ge
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ro
u
p
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o
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P
V
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at
a
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u
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p
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n
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5
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9
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p
.w
m
h
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at
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u
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p
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os
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V
.d
a
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.5
9
8
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u
o.
ag
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ou
p
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n
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V
.d
a
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v
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u
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o
u
p
.p
o
st
P
V
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a
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(b
)
V
is
u
o
sp
a
ti
a
l
d
o
m
a
in
m
o
d
el
.
M
em
or
y
m
o
d
el
k
fo
ld
K
F
O
L
D
IC
S
E
m
em
o.
in
t.
d
at
a
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1
1.
53
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.6
7
m
em
o.
ag
e.
gr
ou
p
.d
at
a
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6
8.
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3
6.
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m
em
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e.
gr
ou
p
.w
m
h
.d
at
a
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6
0.
2
4
3
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m
em
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ou
p
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n
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V
.d
at
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5
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3
6.
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m
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o.
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ou
p
.p
os
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at
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6
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.0
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m
em
o.
in
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d
at
a
-
m
em
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p
.d
at
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1
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m
em
o.
in
t.
d
at
a
-
m
em
o.
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e.
gr
ou
p
.w
m
h
.d
at
a
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.3
1
4.
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m
em
o.
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t.
d
at
a
-
m
em
o.
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e.
gr
ou
p
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n
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.d
at
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m
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o.
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d
at
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-
m
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e.
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ou
p
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p
.w
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m
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p
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p
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p
.d
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p
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3
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p
.w
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p
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6
.7
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m
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ou
p
.w
m
h
.d
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-
m
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p
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p
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(c
)
M
em
or
y
an
d
le
ar
n
in
g
d
om
ai
n
m
o
d
el
.
E
x
ec
u
ti
ve
fu
n
ct
io
n
m
o
d
el
k
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F
O
L
D
IC
S
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ex
fn
.i
n
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at
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u
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.d
at
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.g
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n
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a
-
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.a
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ro
u
p
.w
m
h
.d
at
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n
t.
d
at
a
-
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.a
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.g
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u
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n
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n
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-
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.a
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.g
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u
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a
42
.0
1
18
.7
2
ex
fn
.a
ge
.g
ro
u
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-
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ro
u
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u
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-
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u
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u
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u
p
.w
m
h
.d
at
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u
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7
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u
p
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m
h
.d
at
a
-
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u
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u
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(d
)
E
x
ec
u
ti
ve
fu
n
ct
io
n
d
o
m
a
in
m
o
d
el
.
P
D
-N
=
P
a
rk
in
so
n
’s
d
is
ea
se
n
o
rm
a
l
co
g
n
it
io
n
;
P
D
-M
C
I
=
P
a
rk
in
so
n
’s
d
is
ea
se
m
il
d
co
g
n
it
iv
e
im
p
a
ir
m
en
t;
P
D
D
=
P
a
rk
in
so
n
’s
d
is
ea
se
d
em
en
ti
a
;
M
o
C
A
=
M
o
n
tr
ea
l
C
o
g
n
it
iv
e
A
ss
es
sm
en
t.
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